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Modelling the Impact of Referral Guideline Changes for Mild Dyskaryosis on 
Colposcopy Services in England 
 
Abstract 
 
Objectives. This model examines the effects of changing referral strategies within 
the established structure of NHS cervical screening driven colposcopy practice. It 
considers the effects of the new strategy on colposcopy workload, patient waiting 
times, and associated costs and health benefits. 
 
Methods. By postal survey, the current operational strategies of colposcopy services 
were established by questionnaire with respect to referral practices and management 
protocols. After first-cut piloting, and utilising published and original research, a 
Markovian model was constructed, and the impact of the new strategy was 
determined on colposcopy workload and patient waiting times for three 
hypothetical clinic types. Expected costs and benefits of the new policy were 
assessed through the adaptation of a previous ScHARR cervical screening model. 
 
Results.  Clinic workload is expected to increase by between 21% and 35% within 
three years of the policy change, depending on clinic efficiency in other areas; the 
majority of this impact would be seen within the first year.  It is predicted that 
particularly inefficient clinics would struggle to meet the existing waiting time 
requirements for women referred with low-grade disease, owing to the increased 
level of workload seen throughout the patient pathway as a result of the 
implementation of the new policy.  
 
The impact of the new policy can, however, be mitigated through improving the 
efficiency of existing clinics, by altering policies relating to surveillance of low-
grade disease, post-treatment follow-up, treatment policy (whether or not treatment 
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is performed at the initial colposcopy visit), and through adherence to national 
guidelines. 
 
A cost-effectiveness analysis using the ScHARR liquid-based cytology model 
suggests that the policy change is likely to be have a cost per quality-adjusted life-
year gained of between £1,400 and £5,500 per quality-adjusted life-year gained 
(exclusing the costs of follow-up), which would be deemed acceptable to 
organisations such as the National Institute for Health and Clinical Excellence. 
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2.0 Introduction 
 
2.1 Background to disease 
 
Cervical squamous carcinoma is now the eleventh most common cancer in women in the 
UK, and the eleventh largest cause of cancer deaths, with 1123 deaths attributable to the 
disease in 2002. (1)   Caused by a sexually ‘transmissable’ virus, Human PapillomaVirus 
(HPV), the disease is characterised by a premalignant intraepithelial phase, Cervical 
Intraepithelial Neoplasia (CIN). (2) CIN is subdivided into histologically defined grades 
with different risks of progression to cervical cancer. High-grade disease (CIN 2 & 3) has 
a relatively high risk of progression, whereas low-grade disease (CIN 1) is recognised to 
have a much lower risk. The presence of pre-invasive disease is suggetsed by abnormal 
exfoliative cytology. 
 
2.2 Current structure of services 
 
Cervical cytology screening has been performed at a local level in the UK since the 
1960s. In 1988, the Department of Health required each Health Authority in England to 
introduce a cervical screening programme “for all women aged 20 to 64 to have a smear 
at least every 5 years”. (3)  Through the NHS Cervical Screening Programme (NHS CSP) 
it also published guidelines to facilitate the implementation of this, most importantly the 
introduction of the repeat smear/referral patterns of patients in the target population, 
known as ‘call and recall’. (4) Consequently, the incidence of cervical cancer in the UK 
has fallen more than that of any other cancer: 26% between 1992 and 1997.(5)  
  
There has been much discussion of the relative benefits of changing the screening 
interval for women of different ages. Most notably, Sasieni et al (6) questioned the 
suitability of a uniform screening interval for all women aged 20 to 64 years, and instead 
demonstrated that a 3-year screening interval for younger women offers significantly 
improved disease outcomes, whilst outcomes from 5-yearly screening for women aged 
55-69 is not significantly improved by more frequent screening. 
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The operational strategy of the cervical screening programme requires individual heatlh 
authorities or primary care trusts to be responsible for the ‘call and recall’ for cytology 
results. These are developed in liaison with commissioning primary care trusts, cytology 
laboratories and colposcopy services, under published guidance from the NHS CSP 
directorate. 
 
The decrease in incidence of, and mortality from, cervical squamous carcinoma since the 
introduction of the NHS Cervical Screening Programme is attributed to good coverage of 
the at risk population followed by prompt and appropriate treatment of CIN. (9) Between 
1995 and 1999 the number of newly diagnosed cases of carcinoma fell from 11.0 (10) to 
9.6 (1) per 100,000 women.  It is estimated that cervical screening saves approximately 
1,300 lives per annum (11) It is now recommended that a cervical smear test be offered to 
all women between the ages of 25 and 64, and repeat cytology is performed every 3 years 
to the age of 50, and every 5 years thereafter.  Women over the age of 65 who have had 3 
consecutive normal smears are generally withdrawn from the recall system. (4)   Women 
under 25 are now not invited for screening, as cervical cancer in this age group is rare and 
false positive results are high due to changes in the developing cervix. The proportion of 
eligible women screened within 5 years of their last test has increased from 22 percent in 
1987-88 to just over 80 percent in 2003-04. (5,8)  In 2003-4, a total of 3.5 million women 
were screened under the programme. (7) The annual cost of cervical screening in England, 
including treating cervical abnormalities, is estimated to be around £150 million, or 
£37.50 per woman screened. (12) 
 
Recent research carried out by Peto et al (13) suggests that the introduction of the 
screening programme has prevented a cervical cancer epidemic, which might have led to 
one in sixty-five British women born since 1950 dying from the disease. The authors 
estimate that up to 80% of these deaths would be prevented by screening, but the 
estimates presented are subject to considerable uncertainty in relation to the effects of 
oral contraceptives and changes in sexual behaviour. 
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2.3 Pap screening 
 
Cervical screening involves the patient having regular cervical cytology smears to check 
for pre-cancerous cells. For the majority of patients, this is currently carried out using a 
Papanicolaou smear, a generally quick and painless procedure which involves taking a 
small scraping of cells from an area of the cervix known as the Transformation Zone 
(TZ).  This area is the point where the external (squamous) skin cells meet the internal 
(columnar) cells, and is where the majority of squamous cervical cancers originate.  The 
sampled cells are “smeared” in a layer onto a glass slide and transferred to a laboratory 
for examination by a cytologist. 
 
Analysis of each slide takes approximately six to eight minutes, with the cytologist 
examining for abnormalities known as nuclear dyskaryosis. (7)  The results are classified 
according to the grade of changes seen: mild, moderate and severe, whichrelate to the risk 
of finding cervical disease on further assessment. Smears may also be classified: as 
showing borderline nuclear changes only, representing a lower risk of disease being 
present; as a smear where the cytologist is suspicious of invasive cancer being present; or 
where there is evidence of glandular neoplasia, which is intended to represent a different 
disease process. This method of screening also returns a significant proportion of 
“inadequate” results (9.1%), (8) in which insufficient cells are collected in order for a 
diagnosis to be made, or, more commonly, in which it is impossible to read the slide 
because of contamination with blood or infection.  
 
The number of unstatisfactory smears will be reduced in the near future following the 
replacement of Pap screening with liquid-based cytology (LBC), a test in which the cells 
collected from the cervix are rinsed in a preservative fluid to form a suspension from 
which a layer of cells can be prepared and analysed on a slide. This method improves the 
quality of the slide preparation, allowing faster and possibly more reliable screening by 
laboratory staff, and is associated with a lower inadequate rate - 1.6%  in the NHS LBC 
pilot studies. (7)  A further advantage of this test is that the suspension can be retained and 
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used for further investigations such as testing for HPV-DNA and infections such as 
Chlamydia Trachomatis.  
 
 
2.4 Colposcopy and referral criteria 
 
Women whose smear shows abnormalities necessitating further investigation are referred 
by their primary care team to a colposcopy service, of which there are 178 in England. A 
colposcopy involves a detailed visual assessment of the cervix, with the application of 
indicator solutions. This process may also incorporate a biopsy of any abnormal area, to 
facilitate accurate diagnosis. For any significantly abnormal area, treatment may offered, 
either at the initial diagnostic visit (so-called ‘see & treat’), or at a deferred appointment. 
Although national guidelines exist on the referral of women with abnormal smears, local 
policy tends to dictate the manner and speed with which this happens. Table (1) 
summarises the national referral recommendations for each smear state. 
 
 
Table (1): Recall/referral strategies based on smear result (4) 
Smear result Recommendations for care 
Inadequate · Repeat smear in 3 months 
· If 3 consecutive smears inadequate,  
Refer for colposcopy 
Negative · Patient recalled routinely 
Borderline nuclear 
Changes 
· Repeat smear in 6 months 
· If 3 smears show borderline changes, refer 
for colposcopy 
· If 3 consecutive smears negative,  
Patient recalled routinely 
Mild dyskaryosis · Minimum standard – 2 consecutive mild smears 
triggers referral to colposcopy 
· Best practice – refer after 1 mild smear 
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Moderate dyskaryosis · Immediate referral for colposcopy 
Severe dyskaryosis · Immediate referral for colposcopy 
Suspected Invasive cancer · Target referral colposcopy/gynaecology  
Oncology 
Suspected Glandular 
neoplasia 
· Immediate referral for colposcopy 
 
Previous advice to practitioners and cytologists had stated that referral of patients should 
be made following the return of two mild dyskaryosis smears. (14) It has been recognised 
from clinical trials that a relatively high proportion of women returning a single mild 
dyskaryosis smear have significant cervical disease. The current published guidelines 
acknowledge this evidence, recommending that ‘best practice’ would include the referral 
to colposcopy of all women with single smears returned in this group. Significant concern 
has been expressed as to the ability of colposcopy services to accommodate this increased 
workload. The guideline reflects this concern in recommending that referral after two 
mild smears is acceptable as a ‘minimum standard’.  
 
Other changes new to the current guidelines are the recommendation that patients with 
normal smears, but clinical concerns regarding disease of the cervix, such as post-coital 
bleeding, are not referred for colposcopy assessment from primary care, but rather to 
general gynaecology or genito-urniary medicine.  
 
The new guidelines also include recommendations concerning the age at which women 
are invited to attend screening, and the frequency of repeat cytology.(4) Together these are 
known as “call-recall”. Previous advice recommended that the first smear, or “call” 
smear, should be performed between the ages of 20 to 24 years old. This has been altered 
to the invitation for screening being made at the woman’s 25th birthday. “Recall” smears 
are then recommended at 3 year intervals till the age of 49, and then the interval should 
extend to 5 years. Screening finishes at 65 years old in the presence of 3 previous 
negative adequate smears. Previous advice was screening to 65 years, but no intervals 
were recommended.(8)  
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2.5 Waiting times 
 
The impact on the patients themselves is an important consideration in making policy 
changes, particularly with regard to the time each patient must wait for their initial (and 
subsequent) appointment(s). Current guidelines recommend that women requiring 
referral to the colposcopy service should wait no longer than two weeks for an 
appointment if the smear is reported as representing suspected cancer or glandular 
neoplasia, four weeks for an appointment if their smear shows high-grade disease 
(moderate or severe dyskaryosis), and not longer than eight weeks if the referral smear 
shows low-grade disease (mild dyskaryosis or borderline changes). (4) 
 
 
 
3.0 Aims & Objectives 
 
The project constructs a computer model of current colposcopy practice in the NHS, and 
considers the impact of recommended changes in referral practice with respect to single 
mild dyskaryosis, current and possible changes in recommended colposcopy practice, and 
new “call-recall” strategies. In particular, the model is intended to: 
 
1. Quantify the current number of clinic sessions required in a ‘typical’ colposcopy 
service; 
2. Model the flow of patients through such a ‘typical’ clinic service; 
3. Assess the implications of policy changes on colposcopy workload and waiting 
times in this service, and in the two clinics likely to experience the highest and 
lowest impact of new policy; 
4. Aid national policy analysis and decision-making. 
 
The first model is referred to within this report as the “pathway model”. A second model, 
derived through an adaptation of the ScHARR liquid-based cytology model, is used to 
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assess the impact of the new mild smear policy on the expected costs and health benefits 
associated with the screening programme 
 
 
4.0 Literature Review 
 
Literature on cervical pre-invasive disease is extensive and many sources were utilised in 
the construction of the model. Cytological and histological nomenclature systems have 
changed dramatically since Papanicalaou’s original description of vaginal lavage, and 
Richart’s work into the natural history of cervical ‘carcinoma-in-situ’. (15,16) There are 
variations in cytology classification systems between countries, with the UK retaining its 
own British Society for Clinical Cytology (BSCC) classification, and the rest of the world 
using the Bethesda classification of cytology. (17,18) Colposcopy practice also differs 
significantly between countries. Contained within this review is data predominantly from 
UK studies, where results are directly applicable to the modelling work. Data from other 
countries is included where it is thought to be significant and directly translatable, and 
when data from the UK is not available on a particular outcome. Data sources are 
reviewed in chronological order, in the sections to which they contributed information for 
the model construction. Some data sources provided information for several areas of 
modelling. 
Studies are classfiied (A), where the work was directly used in the Markov state 
transition models, or (B) where the data was used to support modelling, but not directly 
used.  
 
4.1 Previous modelling work 
 
A number of relevant modelling studies were indentified to inform the modelling process 
and to identify methodologies which may be appropriate. 
 
Johnson et al (19) carried out decision analysis regarding the change in policy from referral 
to colposcopy after a single mild dyskaryosis smear to the referral after two mild smears. 
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This work uses a decision tree analysis to establish the likelihood of a patient with mild 
dyskaryosis developing cervical cancer under the two colposcopy service access policies. 
Published work is used to establish the probabilities that disease subsequently occurs in 
each group. It highlights there is a risk that women in both groups will develop cervical 
cancer despite appropriate surveillance. A distinction is made between three year versus 
five year recall policies. Results are presented in terms of cervical cancer incidence. With 
a 5-year recall policy the predicted cancer incidence is 2.0 per 1000 for the repeat 
cytology group compared with 1.6 per 1000 under an immediate colposcopy policy. 
Under the 3-year recall policy, the decision analysis predicts an identical rate of cancer 
incidence under both management strategies. With a repeat cytology policy, economic 
calculations suggest that to save a single referral to colposcopy a total of six smears 
would be taken from four women. 
 
A key paper on modelling of cervical screening is that of Sherlaw-Johnson et al (20), in 
which a stochastic model is used to describe the development and progression of pre-
invasive disease in a cohort of screened women under two referral policies for single 
borderline/mild dyskaryosis: immediate colposcopy and repeat cytology (see also Section 
4.3). The greatest reduction in incidence of cancer presented is effected by increasing 
coverage of the target population. Open colposcopy referral for all grades of cytological 
abnormality, or reducing screening intervals are expected to have a much smaller effect 
on disease incidence.  
 
A US study by Myers et al (21) used a 19-state Markov model to follow a simulated cohort 
of women from 15 to 85 years old moving from normal to HPV infection states over a 1 
year Markov cycle. The study presents prevalence rates of HPV infection by age, and 
progression/regression rates for HPV infection to varying degress of Squamous 
Intraepithelial Lesions (SIL), equivalent to CIN. 
 
A second US study by Birch et al (22) concerned a unique prospective utility measurement 
of the management policies of mild dyskaryosis in a family planning clinic environment. 
One hundred and seventy patients underwent one of six scenarios of care,  three 
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dedicated to repeat cytology (so-called observation) and three to early colposcopy, and 
completed questionnaires to establish utility scores using standard gamble techniques. In 
these groups a comparison is also made between cryotherapy and cone biopsy as 
treatment for CIN. Patients found to be normal following completion of care showed a 
statistical difference in utilities in preference of observational versus early referral. Where 
pathology requiring cryotherapy was discovered, patients preferred immediate diagnosis 
over surveillance. There was no statistical difference in the cone biopsy group.  
The study presents data previously published by the same lead author in the Journal of 
Family Practice, which draws attention for the need to individualise access policies in 
line with patient needs. (23) 
 
Canfell et al (24) reported a modelling exercise of the effects of changing recall intervals 
in UK cervical screening programme: 3 years in women aged 25-49 and 5 years in those 
aged 50-64, with women under 25 years no longer being invited for screening. Based on 
a mathematical model of cervical HPV infection, cervical intraepithelial neoplasia and 
invasive cervical cancer, and published UK age-specific screening coverage rates, 
screening intervals and treatment efficacy. The predicted cumulative lifetime incidence of 
invasive cervical cancer in the UK stated as 1.70% in the absence of screening, and 
0.77% under the previous “recall” policies. A reduction in lifetime incidence to 0.63% is 
predicted following implementation of the new recommendations. Screening women 
aged 20-25 years would have minimal impact, with the cumulative lifetime incidence 
decreasing from 0.63 to 0.61%. 
 
Flannelly et al (25) conducted a cost-effectiveness analysis to compare a policy of 
immediate colposcopy versus cytological surveillance, using data from the Aberdeen 
Birthright randomised trial, in which 145 women were allocated to the immediate 
colposcopy group and 158 women were allocated to the two-year surveillance group. In 
the immediate colposcopy group, 66 women (46%) were found to have CIN 3, whilst in 
the surveillance group, 82 women were referred for a colposcopy, of which 43 had CIN 3 
(or 27% of the 158 women in this group). The analysis reported a cost per extra case of 
CIN 3 detected and treated under a change from a surveillance policy to an immediate 
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diagnosis of £148.22. This study did not take into account the eventual cost of treating 
the women who defaulted during the study and the associated utility loss for these women 
upon their progression to invasive cancer. 
 
 
4.2 Cytology state  transition 
 
The need for two Markov chains is explained in Section 5: one for smear transitions, as 
this determines how and when women get referred to colposcopy, and one for transitions 
in the true underlying histological state. 
 
Giles et al (26)  present the results of a UK-based prospective study of colposcopy in 200 
women referred with mild dyskaryosis. Repeat cytology and colposcopy performed at a 
mean time interval of 8.2 months. In the 143 with a single previous mild dyskaryosis 
smear, the repeat cytology is shown in Table (2) below. 
 
Table (2): repeat cytology in women referred with a single mild dyskaryosis smear (mean 
time 8.2 months from index smear) 
Smear result Number Percentage 
Negative 51 39.8 
Mild dyskaryosis 23 18.0 
Moderate dyskaryosis 28 21.9 
Severe dyskaryosis 10 7.8 
Indequate 16 12.5 
 
Borderline results were not reported in this study, making this data difficult to interpret 
for the model transitions.  
 
The results of a UK-based retrospective and prospective study of the outcome for 225 and 
762 women respectively, with first mild dysaryosis on cytology was reported by Fletcher 
et al (27) . Three smear states recorded: borderline with inflammatory changes; borderline 
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without evidence of inflammation; mild; and moderate  dyskaryosis. Repeat cytology for 
borderline changes was requested at six months, and three months for mild dyskaryosis,  
Table (3) shows the results of repeat cytology for 356 women with mild dyskaryosis: - 
 
Table (3): outcome in patients with initial mild dyskaryosis by classification of 
dyskaryosis in first repeat smear 
 
Repeat cytology 
Number Percentage 
Negative 156 43.8 
Borderline or inflammatory 42 11.8 
Persistent mild 129 36.2 
Moderate 23 6.4 
Severe 6 1.7 
 
The 3-month screening interval for mild dyskaryosis for these women makes this data 
difficult to incorporate within the cytology transition matrix, as does the inclusion of the 
‘inflammatory’ group in the borderline category.  
 
Anderson et al (28)  performed a cross-sectional analysis of a UK-based randomised 
prospective study (the Aberdeen Birthright), which examined the cytological behaviour 
of women with mild and moderate dyskaryosis. Repeat cytology and colposcopy was 
performed on these patients, (Table (4) shows the cytology results); however, the mean 
time from referral to colposcopy and repeat cytology is not stated, and this study is 
therefore of limited use. 
 
Table(4): results of repeat cytology following mild/moderate dyskaryosis 
Smear result Number (%) 
Less severe 88 (40) 
Mild dyskaryosis 67 (31) 
More severe 62 (29) 
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Inadequate 11 (N/A) 
 
The paper does not present a breakdown of these results by the index smears, although it 
is noted that these results are similar between the two groups of women.  
 
Cooper et al (29)  report a UK-based retrospective review of one year’s atypical cytology, 
with comparison made of the results of repeat cytology for 127 women with those of the 
index smear. The results of the last two smears are shown in Table (5). 
 
Table (5): smear results transitions over 6 months 
Last smear (percentage) Last-but-one 
smear Inadequate Negative Borderline/ 
Mild 
Moderate/ 
Severe 
Total 
Negative 1 (1.7%) 55 (91.7%) 4 (6.7%) 0 (0%) 60 
Borderline/Mild 5 (8.9%) 27 (48.2%) 22 (36.7%) 2 (3.6%) 56 
 
The median time interval from last-but-one to last smear is six months. No breakdown of 
smear results in the low and high-grade groups is given, and results are of limited use for 
the modelling exercise. 
 
Hirschowitz et al (30)  report the results of a UK-based case-control retrospective study of 
437 women who underwent routine cervical screening and were found to have their first 
borderline cytological change. The cytology records of these women were examined with 
a mean follow-up period of 73 months, with 22.4% progressing to high grade disease on 
cytology. 
 
Flannelly et al (31)  describe the results of the Harris Birthright Research Centre study, a 
prospective randomised trial with 902 patients recruited to four management strategies 
following mild or moderate dyskaryosis. 793 women completed the study. The first group 
were given immediate colposcopy, the second had cytology followed by colposcopy at 
six months, the third had cytology at six and 12 months with colposcopy at 12 months, 
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while the fourth group had cytology at 6, 12 and 24 months with colposcopy at the final 
visit. Results are given below for the immediate diagnosis group and the six month 
surveillance groups in Table (6). 
 
Table (6): cytological appearance of final smear in women who completed study period 
and whose final cytology was adequate 
Final smear Immediate diagnosis (%) Six months’ surveillance (%) 
No dyskaryosis 67 (31.3) 58 (29.1) 
Mild/moderate dyskaryosis 109 (50.9) 84 (42.2) 
Severe dyskaryosis 38 (17.8) 57 (28.6) 
 
No inadequate cytology rates are given, and no distinction is made between mild and 
moderate groups, although histological outcome is noted to be different between the two 
groups. 
 
The ALTS trial is a US-based prospective trial of management of Atypical Squamous 
Cells of Undetermined Significance (ASCUS) and cytology suggesting Low-grade 
Squamous Intraepithelial Lesion (LSIL), , provides data for low-grade cytology 
transition. Results appropriate for this study are reported by Solomon et al (32). 3,488 
patients were randomised to receive immediate colposcopy, repeat cytology and HPV 
testing or cytology alone following a single ASCUS or LSIL smear. Enrollment cytology 
was performed at an average of 2 months, while 3,470 cytology results of the enrolment 
cytology were available and are shown in Table (7). 
 
Table(7): repeat cytology results following LSIL/ASCUS 
Repeat cytology Number (%) 
Negative  1460 (41.9) 
ASCUS 1134 (32.5) 
LSIL 630 (18.1) 
HSIL 246 (7.0) 
 *HSIL = Cytology suggesting High-grade Squamous Intraepithelial Lesion 
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The study group includes 45% of women whose index cytology was reviewed and found 
to be of a higher or lower grade. Definitions of ASCUS do not correlate exactly with 
borderline nuclear abnormalities, and as such the results are not directly transposable to 
this project. 
 
A study by Rawal et al (33)  report the results of a UK-based prospective cytological and 
histological study conducted in 627 women with first abnormal smear showing borderline 
nuclear abnormality. Data from 534 women were available for study and results from 
repeat cytology in 491 at six months are represented in Table (8). 
 
Table (8): persistence of borderline smears 
Smear result Number 
Normal 268 (50.2) 
Borderline 121 (22.7) 
Mild dyskaryosis 41 (7.6) 
Moderate dyskaryosis 13 (2.4) 
Severe dyskaryosis 5 (0.9) 
Inadequate 43 (8.0) 
 
Key data on the persistence of mildly dyskaryotic smears was extracted from work by 
Woodward et al (34)  on a five-year retrospective study of 269 women returning a mildly 
dyskaryotic smear with no previous cytological abnormality. Included in the data is a 
breakdown of the next smear result, which was performed at 6 months following the 
initial smear. This data is summarised in Table (9). 
 
Table (9): persistence of mild smears 
Smear result Number of women (%) 
Negative 113 (42) 
Borderline 36 (13.4) 
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Mild 85 (31.6) 
Moderate 22 (8.2) 
Severe 12 (4.5) 
Inadequate 1 (0.4) 
 
4.3 CIN state transition 
 
Literature searches identified a number of studies which report the natural history of pre-
invasive cervical disease (i.e. the progression of the true underlying tissue state, as 
opposed to the  transitions between smear states). These data are important in following 
disease in patients undergoing surveillance by colposcopy. 
 
Campion et al (35) carried out a UK-based study designed to gain an improved 
understanding of the natural history of CIN 1. This prospective study of 100 women 
under 30 years old, with a mildly dyskaryotic smear, followed patients for between 19 
and 30 months, during which time each patient was reviewed at 4-monthly intervals with 
both cytology and colposcopy to check for disease progression or regression. Seven 
women showed no signs of cervical disease after a minimum of 19 month’s follow-up, 
while 26 showed evidence of progression to CIN 3 over the same period. However, to 
avoid interfering with disease biology, no biopsies were taken until progression was 
detected, and so the diagnosis relied on the visual inspection at colposcopy of the lead 
author alone. 
 
Oster et al (36) carried out a meta-analysis of published research from 1950 on, into the 
natural history of CIN broken down by disease category. It includes only data where a 
minimal disturbance of the lesion has occurred, excluding studies that have used 
postconisation outcomes. The summary table from this review is shown in Table (10). 
 
Table(10): Results of meta-analysis of disease progression data 
CIN Grade Regress Persist Progress to 
CIN 3 
Progress to 
invasive cancer 
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CIN 1 57% 32% 11% 1% 
CIN 2 43% 35% 22% 5% 
CIN 3 32% <56% - >12% 
 
There is no weighting of the studies for reliablility of evidence, and no time interval for 
changes is incuded in the summary of results. 
 
Sherlaw-Johnson et al (20) describe the development and progression of pre-invasive 
disease in a cohort of screened women. This includes data regarding transitions between 
histological states: normal, CIN 1, CIN 2, CIN 3 and invasive cancer, which is shown in 
the Table (11).  
 
Table (11): Histological disease progression (18) 
To  
 
From 
Negative CIN 1 CIN 2 CIN 3 Inv Ca 
Negative 99.88 0.12 0 0 0 
CIN 1 2 89.5 6 2.5 0 
CIN 2 0 0 85 15 0 
CIN 3 0 0 0 99 1 
Invasive cancer 0 0 0 0 100 
  
Two clinical strategies are compared, colposocpy referral after single mild dyskaryosis 
versus repeat cytology at six months with referral for persistent abnormality. The model 
assumes the screening of women over 18 years old, and predicts the incidence of cervical 
cancer. Modelling is performed with varying screening interval (one to 10 year “recall”); 
varying population coverage (50 to 90%); and varying specificity and sensitivity of 
cytology. At 70% coverage with 3 yearly cytology the incidence of cervical cancer is 
predicted to be 2.00 per 10,000 women over 18 years old with immediate single mild 
referral, compared to 2.10 with repeat cytology. This is significantly reduced by 
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increasing coverage to 90%, but there was little effect of changing screening interval or 
cytology sensitivity/specificity. 
 
A Finnish study by Väyrynen et al (37) is the first in an impressive series of articles on a 
group of patients identified with cervical HPV lesions and reviewed by cytology and 
colposcopy +/- biopsy on a six-month basis. At this stage 286 women had been recruited 
and followed at a mean time of 16.0 months. The basis of the paper is the identification 
of OKT-6+  cells, but data is presented on the overall rate of progression to CIN (19.0%), 
persistence of the HPV lesion (52.1%) or regression to normal (28.8%) over the stated 
time interval.  
 
A Canadian meta-analysis by Melnikow et al (37) used data from 15 studies post-1970, 
relating cervical cytology to outcome following a minimum of six months cytology or 
colposcopy/pathology follow up without treatment. For this analysis, non-Bethesda 
classification systems were adapted. Studies are scored on data quality. Random effect 
models were used to estimate the pooled rates of disease regression to normal, and 
progression to high-grade SIL and cancer. Regression was defined as return to normal 
cytology or biopsy results. Progression was defined as cytology or biopsy showing a 
higher-grade lesion than that at referral. No relation was found between regression rates 
and follow-up intervals. Six-month progression rates are included in the results, which 
are summarised in Table (12). 
 
Table( 12): Results of regression/progression rates for cervical cytology/biopsy in meta-
analysis 
Tissue state Regression 
(no time interval) 
Progression to 
higher-grade 
(at 6 months) 
Progression to 
invasive CA 
(at 6 months) 
ASCUS 68.19% 1.97% 0.06% 
LSIL 47.39% 6.56% 0.04% 
HSIL 35.03% - 0.15% 
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4.4 Colposcopy outcome by referral indication 
 
Data for this part of the model were provided by the Office of National Statistics, derived 
from the national annual cytology service Korner Community returns (KC61) 2003-4.(39) 
Original research was not included in the model as this KC61 constitutes a ‘real world’ 
assessment of the outcome of referral by indication. Research that was considered prior to 
the availability of national data for this year, has been previously extensively analysed 
and presented in systematic reviews and meta-analyses. These summary studies are 
presented below. 
 
Fahey et al (40)  conducted a meta-analysis using a MEDLINE keyword search to identify 
over 500 citations published in English, combining data from 59 to estimate the 
accuracyof the Pap test. The study used a positive/negative dichotomy derived from 
ordinal study results, for both cytologic and histologic thresholds for construction of a 
Standard Receiver Operating Curves (SROC) curve. At the high specificity (90-95%) 
desirable for cervical screening, sensitivity is appreciated to be low (20-35% range). The 
critical appraisal identified “significant deficiencies” in the studies used. 
 
A meta-analysis by Nanda et al (41) utilised MEDLINE, EMBASE, HealthStar, CancerLit 
and CINAHL to identify 94 studies of conventional cytology which allowed construction 
of 2 x 2 tables where colposcopy/histology was performed within three months of the 
referral smear. Other classification systems are integrated into the Bethesda system and 
results for the sensitivity and specificity are shown in Table (13). 
 
Table (13): Summary statistics from meta-analysis of conventional Papanicolaou testing 
Smear/Histology 
Correlation 
Number of studies 
included 
Sensitivity 
(mean) 
Specificity 
(mean) 
ASCUS/CIN 1 37 0.74 0.68 
LSIL/CIN 1 71 0.69 0.81 
LSIL/CIN 2-3 54 0.83 0.66 
HSIL/CIN 2-3 43 0.58 0.92 
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Walker et al (42), a study of women with mild atypia on a cervical smear. Women with 
such an abnormality were classified into one of five categories: normal, atypical, 
abnormal, highly suspicious and conclusive, and had a subsequent colposcopy directed 
biopsy to determine the grade of underlying disease existed. Table (14) shows the 
outcome at colposcopy of these women, divided by the grade of the referral smear. 
 
Table (14): Correlation of smear result with subsequent histology 
 Referral smear 
Histology Normal Atypical Abnormal Highly suspicious Conclusive 
No CIN 17 (22.8%) 14 (16.7%) 1 (1.8) - - 
CIN 1 22 (37.3%) 16 (19.3%) 13 (22.8%) - - 
CIN 2 15 (25.4%) 28 (33.7%) 17 (29.8%) 3 (25%) - 
CIN 3 5 (8.5%) 25 (30.1%) 26 (45.6%) 9 (75%) 3 (100%) 
Total (%) 59 (27.6%) 83 (38.8%) 57 (26.6%) 12 (5.6%) 3 (1.4%) 
 
HPV-NCIN infection was not considered as part of this study, and the interpretation of 
the data is hindered by the uncertainty in the correlation between the smear states used 
and the current classification system. 
 
Robertson et al (43) studied the cytology, histology and clinical records of 1,781 women 
returning a mild dyskaryosis smear between 1965 and 1984, followed until mid-1987. 
The study reported a poor correlation between a single mildly dyskaryotic smear and the 
subsequent biopsy result, although this relationship became more reliable following 
persistence of cytological abnormality. Table (15) shows the main results of the study by 
smear and biopsy result. 
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Table (15): Results of serial smears and biopsies during first two years of follow-up 
 Biopsy result (%) 
Smear result Normal Condyloma 
(HPV 
infection) 
CIN 1/2 CIN 3 Invasive 
carcinoma 
Unknown Total 
Mild dyskaryosis in 
1 or 2 smears with 
biopsy 
101 
 (32%) 
2  
(0.06%) 
173 
(55%) 
38 
(12%) 
1  
(0.3%) 
0 315 
(100%) 
Persisting mild 
dyskaryosis with 
biopsy at 18-24 
months 
19  
(13%) 
2  
(1.4%) 
67 
 (46%) 
39 
(27%) 
0 18  
(12%) 
145 
(100%) 
More severe 
dyskaryosis in 
second or later 
smear with biopsy 
20 
(8%) 
0 115 
(44%) 
124 
(47%) 
3  
(1.1%) 
0 262 
(100%) 
Smear regressed to 
normal 
- - - - - - 625 
(100%) 
 
 
Unfortunately, the biopsy results do not distinguish between CIN 1 and CIN 2, nor is it 
clear exactly when repeat smears were taken, making it difficult to determine the exact 
timing of disease “progression”.  
 
A UK-based prospective study reported by Jones et al,(44) compared two strategies for 
management of mild dyskarosis: cytological surveillance and immediate referral. The 
study was performed retrospectively in units with the different management strategies. In 
one unit, 278 women had cytology surveillance for two to three years if subsequent 
cytology had been normal or borderline, with colposcopy if repeat cytology was abnomal 
(75 patients). Patients not previously seen for colposcopy were asked to attend for 
definitive diagnosis; 144 attended. In the other unit, 191 patients had colposcopy 
 31 
immediately at the first mild smear, 137 had further colposcopy at a mean of 32 months. 
All patients with disease at colposcopy had biopsies to confirm histological grade. 
Results are shown in Table (16), numbers are for patients completing the study in each 
unit. 
 
Table (16): Colposcopy outcome for two different mild dyskarysosis policies 
Cytological surveillance Early colposcopy  
At referral 
colposcopy 
(n=70) 
On study 
colposocpy 
(n=144) 
Total (n = 
214) 
On initial 
colposcopy 
(n=191) 
On study 
follow-up 
(n=137) 
No disease 9 (13%) 54 (38%) 63 (29%) 31 (17%) 87 (63%) 
HPV/CIN 10 (13%) 64 (44%) 74 (35%) 83 (43%) 45 (33%) 
CIN 2 19 (27%) 8 (6%) 27 (13%) 39 (20%) 5 (4%) 
CIN 3 32 (46%) 18 (12%) 50 (23%) 38 (20%) 0 (0%) 
 
Because results are given for surveillance in line with previous two mild dyskaryosis 
smear referral advice, and single mild dyskaryosis colposcopy referral, these results are 
integral to the model design.  
 
 
4.5 Treatment outcome 
 
Most UK studies of the last ten years examine outcome following LLETZ. These were 
reviewed and papers used as modelling data are presented below. One unit in the UK has 
published extensive data on the outcome following destructive treatment of the cervix. 
This is included in this review to demonstrate the similar success rates from treatment by 
these modalities. Overall, treatment success rate is generally assumed to be 90% for 
negative cytology follow-up, and 95% for absence of high-grade disease following 
treatment. This forms the basis of the minimum standards in colposcopy practice, and this 
source was used for direct data entry to the model.(4) 
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Luesley et al (45) carried out a retrospective review of cervical LLETZ. Six hundred and 
sixteen treated  women had abnormal smears and treatment by loop diathermy excision, 
of whom 557 subsequently attended for review with cytology and colposcopy at six 
months. Six month outcome data are recorded in terms of potential failure (cytology 
abnormal) and confirmed failure (histology abnormal), and is summarised in Table (17). 
 
Table (17): Cytological and histological findings following cervical LLETZ 
Cytology findings Histological state 
Normal Abnormal 
Histological failure 
(%) 
CIN 1 84 13 4 (4.1) 
CIN 2 71 7 4 (5.1) 
CIN 3 208 20 9 (4.3) 
Invasive cancer 9 1 1 (10.0) 
 
Gordon et al (46) reported the findings of a UK-based study of the oucome of destructive 
treatment in 1,661 women with two mild dyskaryosis smears or a single moderate/severe 
smear. Follow-up was performed with cytology, with colposcopy only used if smears 
were abnormal. Follow-up protocols are affected by pre-treatment CIN grade. The 
majority underwent diagnosis and treatment at a single visist (‘see & treat’). Studu end 
points included persistent or recurrent histological abnormality (≥CIN 1) in follow-up. 
Ninety-eight percent completed follow-up at four months, falling to 87% at five years. 
Overall a single treatment resulted in restoring normal cytology in 1518 (93%) patients, 
with primary success rates falling from 96% at four months, to 91% at six years plus. 
There was a positive association between age and failure rates. 
 
Murdoch et al (47) presents a study of 721 women who had abnormal or inadequate 
cytology, treated by LLETZ with the intention of complete excision. Women were 
reviewed at three months with cytology and colposcopy where primary incomplete 
excision at the endocervical margin was observed, at three months. The paper reported 
excision margin status, which is reproduced in Table (18). 
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Table (18): Excision margin status in women undergoing LLETZ with intent to treat 
Excision incomplete  Excision 
complete Endo Ecto Both Not 
stated* 
Not 
Stated 
Total 405 106 26 28 96 60 
Percentage 56.2 14.7 3.6 3.8 13.3 8.3 
*Margins incomplete – incomplete margins where the histology does not record 
which are involved 
. 
The finding of residual CIN at three months is then reported by grade of CIN at 
treatment, and is shown in Table (19) below, by grade of CIN treated.  
 
Table (19):Grade of CIN and finding of residual disease at follow-up 
Excision incomplete Histology Excision 
Complete Endo Ecto Both NS 
Not 
stated 
Total 
(CIN) 
Residual 
Disease 
CIN 1 63 2 1 0 10 11 87 1(1.1%) 
CIN 2 69 8 1 2 21 11 112 6 (5.4%) 
CIN 3 273 96 24 26 65 38 522 26 (4.7%) 
Total 405 106 26 28 96 60 721 33 (4.6%) 
 
Finally, the rates of residual disease by excision margin status are reported and are shown 
in the Table (20). 
 
Table (20): Excision margin status and finding of residual disease at follow-up 
Histology report  Number Residual(%) 
Complete 405 7 (1.7) 
Incomplete endocervix 106 10 (9.4) 
Incomplete ectocervix 26 2 (7.7) 
Incomplete endocervix 
and ectocervix 
28 10 (35.7) 
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Incomplete NS 96 4 (4.2) 
Not stated 60 - 
 
A UK-based retrospective case-control study described by Shafi et al (48) was designed to 
determine factors predicting cytological outcome. Fifty eight women with abnormal 
follow up cytology formed the study group, and were compared to a control group of 116 
women treated immediately before or after the study patient. Stepwise logistic regression 
analysis was used to show excision margin status as an independent prognostic indicator 
of cytological outcome. The results for excision margin status are shown in Table (21). 
 
Table (21): univariate analysis of prognosis in cytological outcome by excision margin 
status (at 3 months) 
Cytological follow up Excision margin 
status Normal (n=116) Abnormal (n=58) 
Odds ratio 
Complete 88 33 
Incomplete 15 17 
 
3.02 
 
The second of two publications from a cohort of 1000 women with abnormal cytology 
treated by LLETZ in Bristol, UK (49). If excision was complete, patients were followed by 
cervical cytology for over two years: 94% attending for follow up at 10 or more months, 
and 86% at 22 or more months. If cytology was abnormal patients were seen for 
colposcopy. If excision was initially incomplete patients were additionally seen at 4 
months for cytology and colposocpy. The recurrence/residual CIN rates were 5.0% in the 
first year (median 11 months) and 0.6% in the second year (median 22 months).   
 
Flannelly et al (50) reported a retrospective review of cytology following treatment with 
LLETZ for 1,000 women, 977 of whom attended for at least one interval cytology review 
following treatment. Dyskaryosis was present in the smears of 80 (8.2%) women at some 
time in follow-up. Treatment failure is then defined as histological evidence of CIN 
within four years of follow-up. A number of time intervals are presented; the overall 
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outcome by excision margin status of the 466 women for whom results were available are 
summarised in Table (22). 
 
Table (22): Characteristics of LLETZ treatment failures  
Excision margin 
status 
Number Number with no CIN 
on follow up (%) 
Number with CIN 
on follow up (%) 
Complete 390 367 (94) 23 (6) 
Incomplete 76 65 (86) 11 (14) 
 
Dobbs et al (51) report the results of a retrospective study of 394 consecutive LLETZ 
treatments for CIN. Patients were followed up with cytology at six and 12 months, and 
then annually for a further four years. Patients with abnormal cytology were referred back 
to the service for colposcopy. Outcome data by grade of CIN and excision margin status 
are shown in Table (23).  
 
Table (23): Success of LLETZ for women with CIN 
Incomplete excision Histology Number Complete 
excision (%) Ectocervix Endocervix Total (%) 
CIN 1 56 46 (82) 3 7 10 (18) 
CIN 2 97 78 (80) 7 12 19 (20) 
CIN 3 168 122 (73) 27 19 46 (27) 
Total 321 246 (77) 37 38 75 (23) 
 
Excision status is related to abnormal histology in follow-up (women with both 
ectocervical and endocervical margins involved were re-treated); two women had 
cervical carcinoma in follow-up.  
 
A retrospective review of 3,426 women undergoing cervical LLETZ and a minmum of 
one further colposcopy assessment with cytology was reported by Flannelly et al (52).  
3,386 women had at least one adequate smear in follow-up; the total follow-up period  
comprised 9,765 women years, with a mean duration of 35 months. Four hundred and 
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seventeen (12.2%) women had dyskaryosis on the cytology follow-up: 256 (61%) at the 
first smear, 68 (16%) at the second and 43 (10%) at the third. Univariate analysis 
demonstrated that age ≥50, involved excision margins and incomplete excision at the 
internal margin were associated with increased risk of dyskaryosis. Histological evidence 
of recurrent/residual disease was shown in 298 women.  Six were found to have invasive 
cancer, 146 (49%) had CIN 2 or 3, and 119 (40%) had CIN 1. The same risk factors were 
associated with recurrent or residual disease by univariate analysis. 
 
 
5.0 Methodology 
 
The analyses for this project were carried out using two connected models: -  
 
· A service pathway model, incorporating a waiting time model 
· A health economic model. 
 
The first model focuses on the referral of patients to colposcopy services (including 
women referred from the screening programme and those presenting with symptomatic 
disease), their subsequent treatment, surveillance and follow-up in terms of workload and 
time to access colposcopy. The primary aim was to provide estimates of the impact of 
changing referral and screening policies in terms of colposcopy service workload and 
patient waiting times. The second model was constructed to consider the economic 
impact of the new policies, along with the expected health benefits. 
  
5.1 Colposcopy service pathway model 
 
5.1.1 Modelling theory 
The primary model in the analysis is the service pathway model, which predicts the flow 
of patients from the screening programme into the colposcopy service when referred from 
community-based screening. It incorporates disease diagnosis, surveillance, treatment 
and post-treatment care, both within the service and in the community setting. 
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Consideration is also given to the impact on colposcopy services of women who present 
with symptoms of cervical disease, thereby including those women whose involvement is 
not specifically a result of cytology screening. The model quantifies the impact on the 
number of clinic sessions required in each six month period following the implementation 
of the new guideline on mildly dyskaryotic smears in the three years following the 
introduction of the new policy. This is followed by modelling of the impact of other 
recent changes in screening policy. Three modelled service scenarios are presented, 
representing the breadth of the likely experience of colposcopy services nationwide. 
 
The model uses state transition (Markov) theory to simulate the natural history of the 
disease, from normal cervical epithelium, through the pre-invasive cervical intra-
epithelial neoplasia (CIN) stages and eventually to invasive cancer. The Markov 
methodology allows a finite number of discrete health states to be modelled, with patients 
regression and progression between these states determined by transition probabilities 
which apply to a pre-determined time horizon. In this case, transitions are modelled at six 
monthly intervals, a time horizon within which it is feasible for such transitions to occur, 
and which is amenable to the available published data on disease progression. 
 
Markov theory states that a patient’s health state in the next time period depends only on 
their current health state, and not on health states in previous time periods. This approach 
is particularly useful in the modelling of diseases in which the risk is ongoing, where 
events may occur more than once, and in which the timing of events is important. The 
model uses these transitions to predict the number of women in each health state at any 
given point in time, thus enabling predictions to be made regarding the number of women 
being referred to a colposcopy service following an abnormal smear result. The model 
was developed through a series of interviews with clinicians from which an extensive set 
of conceptual patient pathways were constructed. An excerpt from these sessions is given 
in Appendix 1. The parameters and data used within the service pathway model are 
described in Section 6. 
 
5.1.2 Colposcopy questionnaire 
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In order to establish the current protocols of English services on a number of 
management issues, and of regional variances in community-based smear practice, the 
2004 National Colposcopy Questionnaire was circulated under the auspices of the British 
Society for Colposcopy and Cervical Pathology (BSCCP) and the NHS Cancer Screening 
Programme to all 178 colposcopy services in England. The questionnaire included 
questions on individual policies relating to: - 
 
· Community policies on referral of women with inadequate, borderline and mild  
   smears;  
· Service / community follow-up following normal assessment at colposcopy; 
· Policy regarding management of low grade disease (HPV-NCIN and CIN1), that is 
discharge, repeat colposcopy or treatment; 
· Timing and nature of treatment (i.e. at initial colposcopy visit or at a later visit); 
· Service and community-based follow-up policy after treatment; 
· Clinic appointment strategy. 
 
A draft version of the questionnaire was circulated to a clinician from each of the English 
health regions, from whom feedback and advice was obtained. A number of revisions 
were made based on this pilot to produce the final version of the questionnaire which was 
distributed to the named lead clinicians of all NHS colposcopy services. Responses from 
158 out of the 176 NHS services (89.7%) were processed for the model construction 
(note - two services had merged with other clinics since commencing the modelling 
work). Section 6 describes this data and how it was used to produce example services for 
the main analysis. 
 
5.1.3 Modelled clinic services 
The model was designed to allow the impact of any community or clinic guidelines to be 
assessed in any service, in addition to an estimation of the impact at a national level. 
To this end, three example services were modelled in the main analysis: - 
· High ‘intensity’ service; 
· Low ‘intensity’ service; 
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· National ‘typical’ service. 
 
The characteristics of the “high-intensity” colposcopy service were identified from the 
colposcopy questionnaire returns. This type of service is modelled under the stated local 
policy that patients are seen in colposcopy before returning the nationally recommended 
number of borderline smears. This type of service organises colposcopy based 
surveillance for patients following a normal colposcopy assessment, performs treatment 
at a separate visit from the diagnostic colposcopy, manages low-grade disease 
conservatively, and arranges colposcopy follow-up for all patients following treatment. It 
receives referrals from an area recommending “recall” cytology at 3 year intervals. This 
service would be generating a high clinical workload, due to the higher volume of 
patients being referred to the service from the community, and the intensive surveillance 
and follow-up policies.   
 
The opposite of this type of service was also identified and modelled. The “low-intensity” 
service has clinical and community policies which minimise both the number of patients 
being referred to the service, and the time which they spend under clinical review. This is 
achieved by adhering to national guidelines regarding patients accessing the service, and 
adopting clinical policies including immediate treatment of disease of all grades at the 
diagnostic visit (‘see & treat’) and the discharge of patients with negative colposcopy and 
following treatment back to their primary care provider. It receives referrals from an area 
recommending “recall” cytology every 5 years. These policies would be expected to 
generate a much lower workload than the high-intensity service. 
 
Both service types are assumed to adhere to the previous recommended policy of referral 
of women with mild dyskaryosis after two mildly abnormal smears to allow examination 
of the impact of changing guideline policies. Table (24) summarises the characteristics of 
the low and high-intensity services. 
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Table (24):  Management policies of colposcopy services: High & Low intensity services 
 
The national ‘typical’ service incorporates all combinations of clinic and community 
policies from the questionnaire returns, and applies weights to each policy based on the 
questionnaire responses (e.g. the questionnaire results show that 62% of all colposcopy 
services see patients following two borderline abnormal smears, so the modelled service 
sees 62% of women following two borderline smears, with the remaining 38% being 
referred only after a third borderline smear). The national “typical” policies are shown for 
comparison in Table (25). A more detailed description of how the policies were 
established is given in section 6.5. 
 
 
 
 
Policy Options High intensity 
service 
Low intensity 
service 
2 smears P O Access policy 
(borderline) 3 smears O P 
Yes P O Normal colposcopy 
follow-up 
No O P 
See and treat P O Treatment timing 
(low-grade disease) 
Defer treatment O P 
See and treat P O Treatment timing 
(high-grade disease) 
Defer treatment O P 
See in clinic P O Post-treatment follow-
up 
Discharge O P 
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Table (25): Management policies of colposcopy services - National ‘typical’ service 
policies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Source: 2004 NHSCSP/BSCCP questionnaire 
 
5.1.4 Model phases. 
The model is divided up into two distinct phases: a warm-up phase and a model phase; 
the model results quoted in section 7 of this report refer only to data from the model 
phase. In order to assess the impact of policy changes, it was necessary to simulate a 
scenario which reflected the current workload of each of the three types of colposcopy 
service in terms of the expected number of patients currently in the colposcopy service at 
any time. Since the existing number of women in the system (and at what stage of the 
Policy Options National weighted average 
1 smear 3% 
2 smears 60% 
Access policy 
(borderline) 
3 smears 37% 
1 smear 20% 
2 smears 79% 
Access policy (mild) 
3 smears 1% 
Yes 35% Normal colposcopy 
follow-up 
No 65% 
See and treat 16% Treatment timing 
(low-grade disease) 
Defer treatment 84% 
See and treat 61% Treatment timing 
(high-grade disease) 
Defer treatment 39% 
See in clinic 55% Post-treatment follow-
up 
Discharge 45% 
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diagnosis/treatment pathway they are) cannot be known exactly at any one point in time, 
the model assumed an empty service at the outset i.e. no patients in the service. By 
assuming a constant arrival rate of new patients into the screening programme (based on 
the current national screening statistics), the flow of patients over time was built up to 
reflect current service capacities. This “warm-up” modelling phase was simulated until a 
point was reached at which the number of colposcopy clinic sessions required per 6 
months remained almost constant (known as “steady state”). 
 
With the model having been built up in the warm-up phase to a point which reflected 
current clinic activity and patient flow, the impact of changes to referral guidelines could 
be assessed from that time point onwards. The analysis was conducted in such a way that 
a direct comparison could be made between services continuing with current policies and 
the effects expected if they adopt the new policies. The differences in the number of 
clinic sessions which would be required could be compared between the policies, in 
addition to an assessment of the impact on waiting times of the extra referrals which 
would be induced by the new policy. 
 
5.1.5 Pathway model assumptions 
Given the potential complexity of the flow of patients through the pathway model, a 
number of simplifying assumptions were made regarding timing of treatment, repeat 
treatment for cervical lesions, referral policies from surveillance and post-treatment 
smears, and patient compliance between subsequent appointments. These are outlined 
below: - 
 
§ Women who have a negative initial colposcopy followed by a repeat smear 6 
months later are assumed to be referred back to the clinic for any abnormality on 
this smear (excluding inadequate smears) 
§ All post-treatment smears and surveillance smears following negative colposcopy 
are assumed to be performed in the community and not in the hospital clinic. 
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§ Only women treated for high-grade disease are eligible for annual surveillance 
smears. Those treated for low-grade disease are followed up in accordance with 
their health authority’s guidelines. 
§ Women undergoing annual smears following treatment are assumed to be referred 
back to the colposcopy clinic if any such smear returns an abnormal result 
(excluding an indequate result). 
§ Women under surveillance for CIN 1 are assumed to be treated following 
persistence of disease at 24 months following the initial colposcopy. 
§ DNA rates are assumed to be equivalent for both low- and high-grade referrals. 
§ Patient compliance with both screening and clinic appointments is assumed to be 
independent from one visit to the next. 
§ Women who do not attend a clinic appointment are automatically offered a further 
appointment. If this appointment is not attended, and no previous contact was 
made by the patient, they are discharged back to the smear taker. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 44 
5.2 Waiting time model 
 
One of the key outcomes of any policy change of this nature is the impact which it has on 
the patients themselves. An increase in the volume of patients being referred to 
colposcopy services due to abnormal smears has a direct effect upon the length of time 
each patient could expect to wait for a clinic appointment. A waiting time model was 
therefore constructed to use the estimates of the number of clinic-based appointments 
(calculated in the service pathway model) to provide insight into expected waiting times 
for newly-referred patients.  
 
Since clinic appointments are typically made on a regular basis, the model reflects this 
and considers the weekly flow of patients through the service, based on whether the 
referral smear was low- or high-grade. In each 6-month time period, the number of clinic-
based appointments for colposcopy and treatment is taken from the service pathway 
model, and used to calculate a total clinic time available for that period. This value was 
then compared with the expected number of clinics required to meet the demand to assess 
how quickly newly-referred patients would be seen for their first clinic appointment. 
 
Patients within the model who have already attended the service for their initial 
colposcopy and are thus already on the service register are assumed to have ‘priority’ 
over new patients, since these appointments would for example, be made six months in 
advance in the case of patients entering surveillance or follow-up in the service. New 
patients with a high-grade abnormality on the referral smear would be prioritised next, 
followed by new patients with a low-grade abnormality. New patients who do not get a 
clinic appointment in the week of their referral are pushed forward into the following 
week. At this point, such patients take ‘priority’over patients who are newly-referred in 
that week; as the appointment would be made in the preceding week. The structure of 
these priorities are shown in Figure (1) below. 
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Figure (1): Prioritisation of patients in colposcopy service 
 
This prioritisation sequence indicates that in services which are ‘inefficient’ and clinic 
time is limited, the time which new patients with low-grade disease wait is likely to be 
higher than is the case in more ‘efficient’ services (in some scenarios it is possible that 
because of intensive surveillance and follow-up policies, the services become overloaded 
with patients who are already on the service register, leading to a situation whereby 
newly-referred patients with low-grade disease cannot be seen at any time, unless 
additional clinics are run to accommodate these patients). It is also assumed that 
appointments within the service are made on a weekly basis, with the prioritisation of 
patients made as in Figure (1). 
High-grade 
patients not seen 
in previous week 
Low-grade 
patients not seen 
in previous week 
Patients already 
on clinic register 
High-grade 
patients referred 
in current week 
Low-grade 
patients not seen 
in previous week 
 46 
 
No differentiation is made between the relative importance of different visit types, so for 
example, a diagnostic colposcopy is considered equally important as a treatment visit. 
The model takes account of the difference types of appointment (e.g. diagnostic 
colposcopy appointment, see and treat appointment, and treatment-only appointment) and 
the expected time required for each type of appointment. Based upon consultations with 
clinicians working within colposcopy units, a diagnostic colposcopy is assumed to take 
15 minutes per patient (including a biopsy), a colposcopy appointment combinied with 
treatment (at the same visit) is assumed to require 30 minutes (also including a biopsy), 
and the time required for a treatment visit is taken to be 20 minutes. 
 
The BSCCP questionnaire results showed that, on average, a typical colposcopy unit 
would run 4.5 clinic sessions per week, each lasting for three hours i.e. a total of 13.5 
hours of clinic time would be available per week. All subsequent analyses are based on 
this assumption. The model assumes that patients being referred to the colposcopy 
service during any given 6 month period do so at a constant rate per week. This is 
implemented simply by dividing the number of referrals by 26 weeks.  
 
Once patients are discharged from the service, it is likely that a proportion will require 
further investigation at a later date within the service, having tested positive at a 
subsequent annual screen. Given that such patients have been discharged from the 
service, they are assumed to be new patients when they are re-referred.  
 
A similar prioritisation system was applied to women who are treated at a separate visit 
from their initial colposcopy. Those with high-grade disease (CIN 2/3) are modelled to 
have priority over those with low-grade disease (HPV/CIN1). 
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5.3 Health economic model 
 
The second part of the analysis focused on the expected impact of the new mild smear 
policy on the costs and health benefits associated with the screening programme. This 
was achieved through an adaptation of the ScHARR model used in the recently-updated 
rapid review of liquid-based cytology (LBC) for cervical screening, commissioned by the 
National Co-ordinating Centre for Health Technology Assessment (NCCHTA).(7) 
 
The model provides a macro-simulation of the life experience of women followed from 
the age of 15 to 95 years, and uses state transition methodology to simulate the natural 
history of the disease, the screening programme, adjusted for all-cause mortality. The 
model was originally designed to compare the health economics of LBC compared to 
conventional Pap screening and a policy of no screening, and generates a number of 
health and economic outcomes under a set of screening policy comparisons. The key 
health outcomes are the annual incidence of invasive cancer,the  percentage of women 
having invasive cancer at some point in their life, and the life-years gained, with health 
economic outcomes being generated relating to the cost per invasive cancer avoided and 
cost per quality-adjusted life year (QALY) gained. 
 
Two policies were considered in HTA review regarding referral policies for women with 
abnormal cervical smears. The first such policy assumed that all women with any grade 
of abnormality (i.e. everything but inadequate or negative) would get referred for 
immediate colposcopy. The second policy assumed that only high-grade smears would 
trigger a referral to colposcopy, whilst women whose smear showed borderline changes 
or mild dyskaryosis would be re-screened 6 months later, at which point a second 
abnormality would trigger a referral to colposcopy. The cost aspect of the analysis 
considered the costs of conventional Pap screening, costs of LBC techniques, colposcopy 
costs, along with direct treatment costs (which would vary according to whether the 
treatment was for pre-invasive lesions or for invasive cancer). 
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In order to utilise this model within the context of this project, a number of modifications 
needed to be made to the LBC model. This process included: - 
 
· Updating of costs of Pap smears, colposcopies and treatment; 
· Assessment of the impact for low / high “intensity” clinics (in terms of screening  
   interval and mild referral policy); 
· A revised discounting scheme which is in line with new NICE guidelines (both costs  
   and QALYs discounted at 3.5%); 
· Updating of inadequate rate on Pap smears; (8) 
· Age at first screen changed to 25 years. 
 
A detailed description of these changes is given in Section 6.7. 
There are a number of features of the original LBC model which do not make it entirely 
compatible with the pathway and capacity model. For example, the LBC model assumed 
that all women are treated on a see and treat basis rather than at a separate visit, which 
contradicts the results of the BSCCP questionnaire. Neither does it incorporate  the costs 
associated with follow-up appointments for women treated for CIN or invasive cancer, or 
surveillance colposcopies for women with CIN or HPV. This suggests that the costs of 
the screening programme will have been underestimated, although this is offset 
somewhat in the LBC model by the assumption that all women who have a colposcopy 
require treatment. The referral policies within the LBC model assume that, under the new 
policy, all women with either a mild or a borderline smear would be referred 
immediately, meaning that the model is likely to overestimate the number of referrals. 
Because of these inconsistencies between the two models, the health economic results 
discussed in Section 7 should be interpreted only as broad estimates of cost-effectiveness. 
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6.0 Model Data 
 
The following descriptions summarise the parameters and their values which are used in 
the pathway and waiting time models. 
  
6.1 Population & population growth 
 
Data on a number of demographic parameters were collected to provide inputs for the 
model. Population data from the 2002-03 National Korner Community (KC 53) returns 
reports that the number of women eligible for cervical screening in England was 
12,804,400 – this population encompasses all screen-eligible women aged 25-64.(8)  
Figures from the KC53 returns were used to provide estimates of coverage of routine 
community screening: 80.6% of women had been screened within the last five years, and 
70% within the last three and a half years. In order to model a typical service, the entire 
eligible population was broken down into 176 equally sized groups, to give an estimate of 
the average population covered by each colposcopy service (71,272 per clinic). The 
model is presented in the context of an increasing population, using estimates of annual 
population increase from the Office of National Statistics (ONS). (53)   
 
6.2 Screening Interval 
 
Policies on the screening interval vary nationwide, and are dictated by the local health 
authorities and primary care trusts in discussion with cytology services. The screening 
interval adopted by each health authority falls into one of three categories, the nationwide 
breakdown of which is as follows:(54)   
· 3-year screening interval - 60% of cytology services; 
· 5-year screening interval - 20% of services; 
· Age-related screening interval - 20% of services. 
 
The third category of health authorities have adopted the new recommended policy under 
which women aged 25-50 are screened every three years, and every five years thereafter, 
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up to the age of 64, after which screening stops on the condition that the three preceding 
smears have been negative. 
 
Such differences in policy clearly have an impact upon the number of women being 
screened in any 6-month period, and this has been accommodated in the “typical” service 
model, so that 60% of women are screened every three years, 20% screened every five 
years, and the remainder are screened according to the age distribution of screen-eligible 
women. For the purposes of the waiting time analysis, in which the timing of referrals is 
important, the arrival rate of women into the clinics was assumed to be constant over the 
6-month period. 
 
6.3 Smear data 
 
Data from the KC61 returns on smears examined by pathology laboratories was used to 
form the basis of smear test result distribution on routine recall smears (8) . This data 
relates only to the results of routine smears, and so is not confounded by the different 
distribution of results which might be found in, for example, the smears of women under 
surveillance for a borderline abnormality. Table (26) shows the percentage of smears 
falling into each category in 2003-04: - 
 
Table (26): Smear Results (call / routine re-call smears) 
Smear Result Percentage of all 
smears examined 
Negative 86.88% 
Inadequate 8.55% 
Borderline changes 2.49% 
Mild dyskaryosis 1.23% 
Moderate dyskaryosis 0.43% 
Severe dyskaryosis 0.37% 
Suspected invasive 
carcinoma / glandular 
0.05% 
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neoplasia 
(Source: Statistical Bulletin 2003-04 (7)) 
 
Given the expected differences between patients cytology pre- and post-treatment, 
different data were used to represent smear results for surveillance screens (including 
post-treatment smears, annual smears and follow-up in the community) .(8)  This data is 
shown in Table (27). 
 
Table (27): Smear results (surveillance smears) 
Smear Result Percentage of all 
smears examined 
Negative 85.89% 
Inadequate 7.13% 
Borderline changes 4.21% 
Mild dyskaryosis 1.86% 
Moderate dyskaryosis 0.52% 
Severe dyskaryosis 0.34% 
Suspected invasive 
carcinoma / glandular 
neoplasia 
0.05% 
(Source:Statistical Bulletin 2003-04 (8)) 
 
The similarities in the data given in Tables 26 and 27 seem to reflect the uncertainty 
inherent in the use of the Pap smear as a diagnostic tool, and the fact that it may not 
always be a good predictor of underlying disease.  
 
6.4 Transition probabilities & colposcopy findings 
 
The movement of patients between different health states is one of the key issues in this 
project, specifically the probabilities of transitions between cytology results and disease 
states at six month intervals, and the findings at colposcopy of patients referred with each 
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category of abnormal cytology result. Where possible, published data were used to define 
these transition probabilities and correlations, for use in the model. Where published data 
were not available expert judgement was elicited. 
 
Seven smear states and the reporting of ‘inadequate for assessment’ were used in the 
model to reflect cytology states: - 
 
· Negative (i.e. no abnormality); 
· Inadequate; 
· Borderline changes; 
· Mild dyskaryosis; 
· Moderate dyskaryosis; 
· Severe dyskaryosis; 
· Suspected invasive cancer / glandular neoplasia 
 
Transition probabilities were estimated at 6-monthly intervals for cytology findings, as 
shown in Table (28). These data relate to the likelihood that the smear report of a 
screening eligible woman changes between recommended surveillance intervals. This 
includes the likelihood that either smear is false positive or false negative, or that the 
either smear is over- or under-called, which reflects the recognised nature of cytological 
assessment. Of note, however, is the reporting of cytology as inadequate, where the 
transition interval is taken from national KC61 data and is likely to represent a three 
month interval, as is recommended by national strategy.  
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Table (28): Transition probabilities at 6-months for cervical cytology 
                                                                                       To this state 
 Negative Inadequate Borderline Mild 
dyskaryosis 
Moderate 
dyskaryosis 
Severe 
dyskaryosis 
Negative (9)  0.858 0.071 0.044 0.019 0.005 0.004 
Inadequate (9)  0.759 0.184 0.032 0.016 0.005 0.003 
Borderline 
abnormality (Rawal) 0.546 0.088 0.246 0.084 0.026 0.01 
Mild dyskaryosis 
(Woodward et al)  0.42 0.004 0.134 0.316 0.082 0.044 
Moderate dyskaryosis 
* N/A N/A N/A N/A N/A N/A 
Severe dyskaryosis * N/A N/A N/A N/A N/A N/A 
 
 
 
From 
this 
state 
Susp. Inv. carcinoma * N/A N/A N/A N/A N/A N/A 
* N/A – Not Applicable - no transition from moderate and severe smear states are 
recorded, as these patients will be referred for colposcopy at the ‘index’ smear. 
(Source:Statistical Bulletin 2003-04 (8), Rawal et  al (33)  , Woodward et al (34) ) 
 
The data used for the transitions from a negative smear state to any other state is derived 
from the recent Statistical Bulletin,(8) since this reflects outcomes at subsequent smears 
for women with a previously negative smear. Data on transitions from the inadequate 
group are also taken from the Bulletin, using data which relates to subsequent smear 
results for women undergoing repeat cytology for a previously inadequate smear. Whilst 
this data is not entirely amenable to state transitions over a 6-month period, the absence 
of more suitable data, combined the validation checks performed on the predicted number 
of referrals using the above data, suggest that the data are reliable proxy measures for thte 
transition probablilities. 
 
 Six disease states were also considered to represent progression of the true underlying 
disease as diagnosed at colposcopy (note that these transitions are considered separately 
from the cytology transitions discussed above): - 
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· Negative (i.e. no abnormality); 
· HPV not achieving diagnostic criteria for CIN (HPV NCIN);  
· CIN 1; 
· CIN 2; 
· CIN 3; 
· Invasive cancer. 
 
Transition probabilities for colposcopy findings were estimated at 6-monthly intervals 
from a meta-analysis of the data from a number of published studies as shown in Table 
(29). In this case these represent histologically diagnosed disease states, rather than 
subjective colposcopy  assessments. 
 
Table (29): Transition probabilities for disease states at 6-months 
                                                                                       To this state 
 Normal HPV CIN 1 CIN 2 CIN 3 Cancer 
Normal 99.76 0.12 0.12 0 0 0 
HPV (NCIN)  6.0 92.5 1.5 0 0 0 
CIN 1 1.0 1.0 89.5 6.0 2.5 0 
CIN 2  0 0 0 85.0 15.0 0 
CIN 3  0 0 0 0 99.0 1.0 
 
 
 
From 
this 
state 
Inv. Carcinoma 0 0 0 0 0 100 
 (Source:Sherlaw-Johnson et al (18), Richart et al (14), Campion et al (33), Vayrynen et al (35)) 
 
One of the key drivers of the model concerns the outcome of colposcopy, which varies 
according to the severity of the referral smear. Such data has been collected from a 
number of studies, (ONS KC data (39) , Jones et al. (44) ), the results of which are shown in 
Table (30). Again, these constitute histologically confirmed disease states.  
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Table (30): Colposcopy result by referral smear result 
Colposcopy findings (%)  
Referral 
smear 
Negative HPV- 
NCIN 
CIN 1 CIN 2 CIN 3 Cancer 
Inadequate 
 
53.74 16.46 20.45 6.48 2.62 0.25 
Borderline 
nuclear 
abnormality 
29.55 20.73 30.86 10.18 8.00 0.67 
1st mild 
dyskaryosis 
34.0 6.0 24.0 22.0 13.0 1.0 
2nd mild 
dyskaryosis 
26.0 11.0 26.0 20.0 15.0 2.0 
Moderate 
dyskaryosis 
7.20 5.05 17.95 36.23 32.71 0.87 
Severe 
dyskaryosis 
3.55 1.92 5.06 15.00 70.73 3.75 
?Inv/ ? 
Glandular 
15.18 2.47 4.93 5.50 33.78 38.14 
(Source: ONS-KC61 national data returns (8),  Jones et al (44)) 
 
6.5 National colposcopy practice data 
 
Given below are some of the key results from the questionnaire responses which have 
been used to form inputs to the model.  
 
6.5.1 Access policies 
Practice was expected to vary in the number of low-grade smears required to trigger 
colposcopy in the different services. The questionnaire included a tick-box for one, two 
or three smears of each type triggering referral, with a free-description area to discuss 
discretionary policies. Table 31 summarises the breakdown of local health authority 
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referral policies for borderline and mildly dyskaryotic smears (for the purposes of the 
model, all services are assumed to see women after three consecutive inadequate smears). 
 
Table (31): Smear referral policies 
Smear result 
Number of abnormal smears 
required  before referral 
Number of 
services 
As a percentage of  
responding services 
1 4 3.2% 
2 92 60.3% 
Borderline 
abnormality 
3 56 36.5% 
1 27 20.4% Mild 
dyskaryosis* 2 119 79.0% 
 (Source: BSCCP/NHSCSP National colposcopy questionnaire 2004)  
 
All patients returning cytology with moderate or severe dyskaryosis, or those with 
suspected invasive cancer or glandular neoplasia should be referred for colposcopy 
immediately. 
 
6.5.2 Surveillance policies following normal colposcopy 
Where the result of colpscopy is a negative assessment after referral, patients may be 
managed in a number of ways. The majority of services were expected to discharge the 
patient back to the care of the referring practitioner for repeat cytology at 6 months, 
whereas a smaller number were expected to follow-up in the colposcopy service at a 
specific time interval. The questionnaire included a tick-box for the expected policies, 
with a free-description area to describe protocols relating to referral smear, patient age, or 
where two different policies were used in a single unit. The results are shown in Table 
(32). 
 
6.5.3 Management of low-grade disease 
The significance of the pre-invasive potential of CIN 1 is debated, and some services 
routinely offer treatment for this condition. Services were questioned regarding treatment 
of CIN 1, and management of patients not treated. Services were also questioned as to 
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their policies of care for patients whose colposcopy assessment demonstrated evidence of 
HPV infection which does not achieve histological criteria for CIN, which was expected 
to constitute a low risk diagnosis. The results for surveillance policies are summarised in 
Table (32). 
 
Table (32): Follow-up / surveillance policies by first colposcopy result 
Colposcopy findings Follow up policy 
(colposcopy only) 
Number of 
services 
As a percentage 
of 
responding 
services  
Not seen in clinic  103 67.8% 
See in 6 months 44 28.9% 
 
Normal 
See in 12 months 5 3.3% 
Not seen in colp 84 56.6% 
See in 6 months 52 35.5% 
 
HPV NCIN* 
See in 12 months 12 7.9% 
Not seen in clinic 29 19.3% 
See in 6 months 104 70.3% 
 
CIN 1 
See in 12 months 13 9.7% 
*HPV NCIN = HPV changes not reaching CIN 
(Source: BSCCP/NHSCSP National colposcopy questionnaire 2004)  
 
In all situations where returned data contained free description of policies affected by age 
of patients these were weighted with respect to the national data regarding screened 
patient demographics.  
 
6.5.4 Type and timing of treatment 
Tables (33) & (34) show the results of the questions relating to the type of treatment 
women with various grades of cervical abnormality at the referral smear would receive. 
Treatment is either carried out at the same visit as the colposcopy , so called ‘see & treat’, 
or at a later visit, ‘deferred treatment’. Treatment is either administered excisionally or 
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destructively within the colposcopy service. Destructive treatment may not be used on a 
‘see & treat’ basis as national guidelines require patients to have a histological diagnosis 
prior to non-excisional treatment.Almost all high-grade lesions will be treated. The 
questionnaire indicated that 30.1% of patients with CIN 1 are treated, the presented data 
relate to this treatment group.   
 
Table (33): Treatment policy: patients with low-grade disease - of those treated  
Policy Proportion of 
services 
Treat on a “see and treat” basis* 15.7% 
Treat at a later visit (deferred treatment)      84.3% 
 
    - treat excisionally (deferred)                   88.9% 
    - treat destructively (deferred)                  11.1% 
 (Source: BSCCP/NHSCSP National colposcopy questionnaire 2004)  
 
Table (34): Treatment policy: patients with high-grade referral smear 
Policy Proportion of 
services 
Treat on a “see and treat” basis* 61.0% 
Treat at a later visit (deferred treatment)      39.0 
 
    - treat excisionally (deferred)                   88.9% 
    - treat destructively (deferred)                  11.1% 
 (Source: BSCCP/NHSCSP National colposcopy questionnaire 2004)  
 
Services not immediately treating CIN 1 were questionned regarding the length of 
conservative follow-up prior to recommending treatment if the disease persisted. These 
results are summarised in Table (35).  
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Table (35): CIN1 time-to-treatment for services offering follow-up 
 
 
 
 
 
 
 
 (Source: BSCCP/NHSCSP National colposcopy questionnaire 2004)  
 
6.5.5  Post-treatment follow-up 
Post-treatment follow-up is a key clinic management variable which affects the number 
of appointments generated per patient. Interpretation of published research regarding risk 
of further disease following treatment was expected to create the greatest variation in 
policies. The histology report following excisional treatment is most often used as the 
indicator of recurrent/residual disease risk, with involved margins and those treated for 
high-grade disease triggering further colposcopy assessment. Table (36) summarises 
nationwide policies on follow-up: -  
 
Table (36): Post-treatment clinic policies 
Histology result Number of services (%) 
Not seen 33 (21.0) 
Involved margins 28 (17.8) 
Involved internal  
Margins 
33 (21.0) 
Involved external 
Margins 
1 (0.6) 
Involved margins or 
high-grade disease 
4 (2.4) 
Invoved internal margins 
or high-grade disease 
5 (3.0) 
Time to treatment Proportion of services adopting 
this policy 
Treat at 6 months 17.2% 
Treat at 12 months 24.1% 
Treat at 18 months 20.7% 
Treat at 24 months 37.9% 
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High-grade disease 2 (1.2) 
See all 50 (31.8) 
(Source: BSCCP/NHSCSP National colposcopy questionnaire 2004) 
 
Using the published research from Murdoch et al, (45) the responses were weighted to 
represent the expected distribution of histology reports following treatment. Patients are 
divided into two groups: those seen in colposcopy and those followed by cytology alone. 
Some services follow patients thought to be at increased risk following treatment for pre-
invasive disease on more than one occasion.These policies were included in the 
weighting process, which are shown in Table (37).   
 
Table (37): Post-treatment clinic policies (following weighting) 
 
 
 
 
 
 
 
(Source: BSCCP/NHSCSP Questionnaire 2004) 
 
6.5.6 Clinic time data 
Services were asked as to the number of number of clinic sessions per week and the 
number of patients seen per clinic in doing so specifying whether the clinics were 
diagnostic only, treatment only, “see & treat”, or a combination of these.  
 
6.6  Attendance parameters 
 
The compliance of patients at diagnosis, treatment, surveillance and follow-up has a 
direct impact upon service workload. Given the new guidelines on women who do not 
attend (DNA) at their initial visit (such patients are now offered a further appointment 
Post-treatment policy Proportion of 
services 
Discharge patient to GP or smear 
only within the service 
44.9% 
Offer repeat colposcopy 6 months 
post-treatment 
55.1% 
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rather than being discharged to their GP as was previously the case), this is particularly 
important when attempting to model patient volume. Data from the 2003-04 KC65 
returns  were used to give the compliance figures shown in Table (38). (8) 
 
Table (38): Attendance rates by visit type 
Appointment 
type 
Proportion who 
attend 
Proportion who 
cancel 
Proportion who DNA 
Initial visit 78% 12% 10% 
Treatment 82% 11% 7% 
Follow-up 69% 16% 15% 
(Source: ONS-KC61 national data returns (8)) 
 
It was assumed in the model that appointments cancelled by the service, or where prior 
notice was given by the patient, would be re-scheduled. Patients who did not attend their 
appointments with no prior cancellation would be discharged back to the referring 
clinician. However, the model retains the capacity to model policies of routinely 
arranging further appointments after all non-attendance. In terms of appointment 
scheduling, it is assumed that the appointment slot taken by a patient who DNAs cannot 
be filled by another patient. This does not apply to patients who cancel their appointment, 
or whose appointments are cancelled by the service. 
 
6.7 Economic model parameters 
 
The additional costs associated with the new policy are modelled using three separate 
cost components, relating to screening, colposcopy and treatment. These costs were taken 
from the updated HTA review (7) and from NHS Reference Costs, where applicable. 
Table (39) summarises these costs: - 
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Table (39): Unit costs used in economic model 
Cost item Unit cost Reference 
Pap Smear (in community) £22.51 Karnon et al – uplifted to 2004 price (7) 
Colposcopy (including any 
treatment) 
£192.35 Cost of gynaecology outpatient visit – 
uplifted from Karnon et al to 2004 price(7) 
Surgery for invasive cancer £2,194.93 NHS Reference Costs: TNELIP HRG 
(M07) (55) 
 
The Pap smear cost includes the cost of a GP’s time plus the slide processing and 
repoting cost. The model assumes that the same cost of colposcopy is applied to all 
women, regardless of whether or not they require treatment. The colposcopy cost of 
£192.35 is the cost of a colposcopy plus treatment (i.e. a see and treat appointment), 
which is applied to all women who attend for a colposcopy, regardlesse of whether or not 
they require treatment, and is therefore likely to overestimate the costs associated with 
the initial colposcopy. This may be offset somewhat by the fact that some clinics would 
treat at a separate appointment, which would incur the cost of a further appointment.  
Data from the Statistical Bulletin was used to update the rate of inadequate smears to a 
figure of 8.55% of all smears, while discount rates of 3.5% were applied to both costs and 
QALYs, in line with guidance issued by the National Institute for Clinical Excellence.
 (56)  
Estimates of the coverage of the screening programme were also estimated from the 
Statistical Bulletin, with figures of 80.6% and 70.3% used for the 5-year and 3-year 
screening intervals respectively. Data from the questionnaire returns was used to reflect 
the national average policy on the timing of treatment, either at the initial colposcopy 
visit or at a later appointment. For patients undergoing treatment for low-grade disease, 
15.7% are assumed to be treated at their initial visit, compared with 61% of patients 
requiring treatment for high-grade disease. 
 
In order to determine the health gains associated with the introduction of the new policy 
in terms of additional QALYs, utility estimates for three health states were taken from the 
HTA review (7). Women diagnosed with invasive cancer of the cervix are assumed within 
the model to have a utility of 0.6, reflecting the deterioration in quality of life for these 
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patients. There are also assumed to be minor utility decrements associated with 
undergoing a colposcopy (a decrement of 0.03 is applied to these patients) and for 
women whose initial smear shows a borderline abnormality but are not referred to 
colposcopy until they return a second borderline result (for whom a utility decrement of 
0.02 is applied).  
 
 
7.0 Results 
 
This chapter summarises the results of the three service types under consideration (the 
“typical” service as a measure of nationwide impact, the “high-intensity” service, and the 
“low-intensity” service). It should be emphasised that the presented data relate to 
colposcopy workload generated by abnormal cervical cytology only, and does not 
represent any practice relating to colposcopy performed for other indications, for example 
patients referred with symptoms of cervical disease. In each case, estimates of the total 
colposcopy workload per six month period in terms of total number of clinic sessions are 
presented, over the first 36 months of the implementation of a new mild smear referral 
policy. For each service this is then followed by a calculation of the changes in the 
different areas of colposcopy clinic activity: new referral, surveillance and treatment. In 
this context, treatment denotes any appointment where treatment is performed, either 
exclusively, or in combination with diagnosis (so-called “see & treat”). Data is then 
presented to show the expected change in detection of high-grade disease as an indicator 
of screening/colposcopy success. 
 
The impact on waiting times are given, followed by the results from the adaptation of the 
ScHARR LBC model are given to allow comparison of the effect of the new policy in 
terms of the additional costs and associated health benefits associated with the screening 
programme.  
 
Finally, clinic protocol modifications that might be introduced to ameliorate the predicted 
workload implications are presented, along with the effects these have on the detection of 
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high-grade disease, where relevant. Included in this section are the results of the impact 
of new “call-recall” recommendations on projected workload increases under a single 
mild referral policy. 
 
 
7.1 Results of “typical” service analysis 
 
As explained in section 5.1, this service service constitutes an “average” of colposcopy 
practice across England. This includes the 20% of services who currently already receive 
women after a single mild smear.  
 
7.1.1 Total clinic workload 
Data for the total clinic workload are presented below in two formats in Figure (2) and 
Table (40). The first format is the projected current and increased number of “typical” 
clinics required for the service per modelling  interval (six-months) under current and 
single mild referral strategies. This may be difficult to interpret on a clinical practice 
basis, and is therefore followed by the second format, the percentage increase in 
workload expected under the single mild referral policy. This percentage increase also 
represents the expected change in number of colposocpy appointments for abnormal 
cervical cytology required nationally to accommodate the increased workload generated 
by referral after a single mild dyskaryosis smear.  
 
 
 
 
 
 
 
 
 
 
 65 
Figure (2): 'typical' service - implications of single mild policy change with respect to 
total clinic workload 
Figure (ii): 'typical' service - implications of single mild 
policy change with respect to total clinic workload
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Table (40): Percentage increase in clinic workload for the “typical” service under the 
one mild policy 
Time since new policy implementation  
6 months 12 months 18 months 24 months 30 months 36 months 
% change in workload 
with single mild policy 
22.0 
 
24.3 
 
21.0 
 
20.9 
 
20.9 
 
20.6 
 
 
The majority of the impact is therefore expected to be seen within 6 months of the policy 
change, with a predicted increase in clinic workload of 22%, and hence a proportional 
increase in the number of clinics required to meet the demand. This increases slightly at 
12 months following the implementation of the policy, and then decreases to around 21% 
before appearing to level off. The sharp increase seen within the first year is attributable 
not only to the additional referrals of women with mild dyskaryosis on the recall smear, 
but also to those women who return a mild result when under surveillance for a 
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borderline or inadequate smear on routine “recall”, and to those who are under 
surveillance from a mild smear prior to the change in referral policy. The lower figure at 
18 months and thereafter, can be attributed to the latter group of women no longer being 
under surveillance. It should be noted that these figures are likely to overestimate the 
total number of referrals, since this analysis assumes that women are screened every three 
years up to the age of 50, and every five years thereafter up to the age of 64. Although 
these are now the recommended screening intervals they were, until recently, relatively 
rare in practice, and the cut-off age at which women are screened every five years may be 
somewhat lower than age 50. 
 
7.1.2 Workload change by type of clinical activity 
The distribution of workload by type is presented in Figure (3) and Table (41), in terms 
of percentage change in three areas of clinical activity: new referral workload, 
surveillance appointments and treatment appointments. This is presented for service 
planning, to identify where colposopy services will expect to find changes in workload. 
In this situation “treatment” activity describes any appointment where treatment is 
performed, either “see & treat” or deferred appointment. 
 
Figure (3): "typical" service- percentage changes in clinical workload by clinical activity 
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Table (41): Percentage increase in clinic worklad  for the “typical” service under the 
one mild policy, by clinical activity 
Time since new policy implementation  
Clinical activity 6 months  12 months 18 months 24 months 30 months 36 months 
New referrals 51.9 28 26.4 26 25.9 25.9 
Surveillance 0.5 23.9 21.4 22 21.7 21.7 
Treatment 24.2 17.6 16.1 16.6 17.6 17.2 
 
This breakdown of the clinic workload demonstrates the impact seen not only in terms of 
the additional initial colposcopies required, but in terms of further appointments for these 
patients, such as surveillance colposcopies and treatment appointments. Clearly within 
the first 6 months, the impact is seen most prominently in the number of new referrals 
and treatment visits. The surveillance appointment workload increases sharply after 6 
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months, since it is during this period that the new referrals from the first 6 months would 
be followed up. 
 
7.1.3 Total workload change and detection of high-grade disease 
Detection of high-grade disease is presented to represent the outcome of cerivical 
screening and colposocpy. The ultimate goal of screening is the treatment of pre-invasive 
disease, and where changes of policy are to be introduced, it will be important that this is 
seen to have no effect on, or improve the detection of, high-grade CIN. This is presented 
with increased total workload to highlight the benefits resulting from the extra resources 
required, in Figure (4) and Table (42). 
 
 
 
 
 
 
 
 
Figure (4):"typical" service- total workload increase vs detection of high-grade disease 
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Table (42):  Percentage increase in detection of high-grade disease for the “typical” 
service under the one mild policy 
Time since new policy implementation  
6 months 12 months 18 months 24 months 30 months 36 months 
Change in detection of 
high-grade disease 36.6 17.4 16.6 16.7 16.7 16.5 
 
These results indicate that although clinic workload is expected to increase significantly, 
the policy change will increase the detection og high-grade disease by around 17% after 
two years. This could be expected to decrease after 3 years, since the women screened 
immediately following the policy change would be more likely to be free of disease than 
under the previous mild referrals policy. 
 
 
7.1.4  Waiting times 
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The impact of the new policy on patient waiting times is driven by the number of 
appointment slots available for new referrals within each service’s capacity planning. The 
waiting time analysis used a number of scenarios by varying the assumptions regarding 
how many clinics each colposcopy service would run per week.  
 
Under the assumptions used in the “typical” service analysis, the impact of the new 
policy on units running 4 or more clinics per  week would be negligible in terms of 
capacity issues, since there would be enough space on the clinic registers for the 
additional referrals to be seen within the recommended period of time. This may, 
however, have staffing implications from time to time given that units are likely to run 
the number of clinics required in a given week to meet the demand, rather than running 
the same number of clinics each and every week. 
 
Problems with failure to meet waiting time criteria would be expected in units of this 
nature which run 3 or fewer clinics per week. Since high-grade referrals have priority 
over those with low-grade smear abnormalities, the impact on waiting times is greatest 
amongst the latter group of patients. By the end of the first year following the change in 
the policy, it is anticipated that women referred with low-grade abnormalities may have 
to wait up to 9 weeks for their initial appointment in the colposcopy clinic. This is due 
primarily to the increase in referrals, but is also due to the additional follow-up and 
surveillance workload associated with these patients. Because the waiting list of these 
patients would continue to rise in the absence of additional clinic capacity, this waiting 
time would be expected to continue to rise. This impact could be offset by improving the 
efficieny of the policies influencing patient flow. 
 
 
 
 
 
 
7.2 Results of “most efficient” service analysis 
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As discussed in section 5.1, this service is presented as the service likely to produce the 
minimum number of colposcopy appointments for patients referred with abnormal 
cytology. It is assumed for the purpose of this study that this service currently operates a 
two mild dyskaryosis access policy. The characteristics of these service are: - 
 
· Access to colpscopy after 3 borderline smears; 
· Screening of women every 5 years; 
· Discharge patients with negative result, HPV or CIN1 at colposcopy; 
· See and treat all patients; 
· Don’t follow up post-treatment (discharge back to community cytology). 
 
It is important to note that screening of women every five years would not be considered 
an acceptable practice for any health authority; this is modelled simply to indicate the 
differences in colposcopy workload for a spectrum of scenarios. 
 
7.2.1 Total clinic workload 
Data for the total clinic workload are again presented in two formats in Figure (5) and 
Table (43): the projected current and increased number of clinics required for the service 
per modelling interval (six-months), and the percentage change in workload. 
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Figure (5): "most efficient" service- implications of single mild policy change with 
respect to total clinic workload 
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Table (43): Percentage increase in clinic workload for the theoretically“efficient” 
service under the one mi ld policy 
Time since new policy implementation  
6 months 12 months 18 months 24 months 30 months 36 months 
Change in workload with 
single mild policy 55.8 42.4 36.3 35.5 34.8 34.9 
 
Owing to the efficiency of this theoretical clinic type, the percentage increase in clinic 
workload is seen to be greater than for the “typical” clinic. However, theis is due to the 
high efficiency of the clinic prior to the policy change – the direct increase in the number 
of clinics required is in fact smaller than for the “efficient” clinic type, with 
approximately 10 additional clinics required per 6 months after two years. The pattern in 
the numbers (when compared to the “typical” clinic) is similar, with the highest increase 
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seen in the first six months, owing to the additional referrals from the inadequate and 
borderline surveillance groups. 
 
7.2.2 Workload change by type of clinical activity 
The distribution of workload by type for this service is again presented in terms of 
percentage change in each area of clinical activity, in Figure (6) and Table (44). This 
service offers very little colposocpy surveillance, as patients with all grades of CIN are 
treated, and normal and patients post-treatment are discharged.  
 
Figure (6):"most efficient" service- percentage changes in clinical workload by clinical 
activity 
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Table (44): Percentage increase in clinic activities for the theoretically “efficient” 
service under the one mild policy, by clinical activitiy 
Time since new policy implementation  
Clinical activity 6 months  12 months 18 months 24 months 30 months 36 months 
New referrals 82.6 47.7 47.1 45.7 45.6 45.6 
Surveillance 0.6 17.7 11.6 15.2 13.4 17.0 
Treatment 45.8 28.6 24.1 23.9 23.7 24.0 
 
These figures again indicate that the additional low-grade referrals impact on clinic 
workload beyond the initial visit, with subsequent increases in treatment and surveillance 
appointments generated and sustained over time. The shape of the three curves differs 
slightly from those derived from the “typical” clinic analyses (see Figure 3), due to the 
different policies adopted. For example, the “treatment” curve peaks earlier under the 
“efficient” clinic scenario since this type of clinic treats all of its patients on a see and 
treat basis, rather than entering some of them into a surveillance programme. 
Furthermore, the “surveillance” curve is lower for the “efficient” programme than for the 
“typical” programme, since women are discharged post-treatment and not followed up. 
 
 
 
7.2.3 Total workload change and detection of high-grade disease 
Detection of high-grade disease is again presented to represent the outcome of cervical 
screening and colposocpy along with total workload increases, presented in Figure (7) 
and Table (45).  
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Figure (7): "most efficient" service- total workload increase vs detection of high-grade 
disease 
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Table (45):Percentage increase in detection of high-grade disease for the “efficient” 
service under the one mild policy 
Time since new policy implementation  
6 months 12 months 18 months 24 months 30 months 36 months 
Change in detection of 
high-grade disease 57.2 26.4 25.7 25.1 25.0 25.0 
 
The greatest impact on detection of high-grade disease is seen within the first 6 months, 
for reasons discussed previously. Thereafter, the detection is expected to be 25% higher 
than under the previous mild dyskaryosis policy, broadly mirroring the increase in clinic 
workload associated with the policy change. 
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7.2.4 Waiting times 
A similar analysis was conducted for this clinic type to that presented in Section 7.1.4. 
Since this efficient type of clinic is intended to give a lower bound on the expected 
additional workload associated with the new policy, the impact on patient waiting times 
is expected to be low. Patients referred to efficient units running at least 2 clinics per 
week would not be affected greatly, with both new low- and high-grade referrals being 
offered an initial appointment within the required time horizon. The impact in such units 
would be seen in terms of the additional referrals, though the non-intensive clinic policies 
adopted mean that these patients only generate a small number of appointments for 
follow-up or surveillance, and so the impact upon patient waiting times (for the initial 
appointment) is likely to be minimal. 
 
The waiting time model suggests that waiting times would only be affected significantly 
if such units were running only one clinic per week. In this instance, it is anticipated that 
a backlog of low-grade referrals would build up very quickly because of a lack of clinic 
capacity, a situtation which would deteriorate over time in the absence of additional 
clinics, as the waiting list increases in length. It is not anticipated that high-grade referrals 
would be affected in this way, given the existing capacity. 
 
 
7.3 Results of “least efficient” service analysis 
 
As discussed in section 5.1, this service constitutes a service identified as likely to 
produce the maximum number of colposcopy appointments for patients referred with 
abnormal cytology. This service currently operates a two mild dyskaryosis access policy. 
The characteristics of these service are: - 
 
· Refer after 2 borderline smears 
· Screen all women every 3 years; 
· Surveillance for negative colposcopy; 
· Surveillance for CIN1 (treat at 24 months); 
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· Colposcopy and treatment take place at separate visits; 
· Follow-up in the service (i.e. with further colposcopy). 
 
7.3.1 Clinic workload 
Again, the total clinic workloads are presented in two formats: the projected current and 
increased number of “least efficient” clinics equired for the service per modelling  
interval (six-months); and the percentage change in workload, in Figure (8) and Table 
(46). 
 
Figure (8): "least efficient" service- implications of single mild policy change with 
respect to total clinic workload 
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Table (46): Percentage increase in clinic workload for the theoretically “inefficient” 
service under the one mild policy 
Time since new policy implementation  
6 months 12 months 18 months 24 months 30 months 36 months 
% change in workload 
with single mild policy 
19.1 
 
26.2 
 
22.3 
 
22.8 
 
26.5 
 
27.0 
 
 
It is noticeable that the percentage increase in clinic workload within the first 6 months is 
considerably lower than for the two other clinic scenarios discussed previously. This is 
due to the inefficiency of such clinics prior to the policy change i.e. the clinics were 
already overworked because of the extensive follow-up and surveillance policies adopted 
that the additional referrals make less of a difference in terms of percentages. However, 
when the absolute increase figures are considered, it can be seen that a 26% increase in 
clinic workload for this inefficient clinic equates to approximately 30 additional clinics 
being required per 6 months to meet the additional demand. It should be noted that the 
predicted workload decreases after 12 months and then begins to rise again. This is due to 
the high number of follow-up and surveillance appointments generated by the initial 
cohort of new patients.  
 
7.3.2  Workload change by type of clinical activity 
The distribution of workload by type for this service is again presented in Figure (9) and 
Table (47), in terms of percentage change in each area of clinical activity. This service 
operates significant  numbers of colposocpy surveillance appointments, as patients will 
have further colposcopy both if assessment is normal, CIN 1 and following treatment.  
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Figure (9)  "least efficient" service- percentage changes in clincal workload by clinical 
activity 
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Table (47): Percentage increase in clinic activities for the theoretically “inefficient” 
service under the one mild policy, by clinical activity 
Time since new policy implementation  
Clinical activity 6 month 12 months 18 months 24 months 30 months 36 months 
New referrals 64.2 37.0 33.9 33.4 33.2 33.2 
Surveillance 0.7 25.5 22.8 22.3 27.0 29.7 
Treatment 26.9 16.0 15.3 16.1 28.4 25.8 
 
The results are similar to those from the “typical” clinic type (see Figure 3), in that the 
immediate impact is seen in terms of the additional mildly dyskaryotic referrals, which 
then has a knock-on effect upon the treatment and surveillance workload. It is likely that 
the number of surveillance appointments required would continue to increase given the 
additional referrals combined with the intensity of the follow-up period. The increase in 
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the number of women treated seen between 24 and 30 months reflects the policy of this 
clinic type with regard to CIN 1 management; women whose initial colposcopy showed 
CIN 1 would be offered repeat colposcopies at 6 month intervals up to 24 months after 
the initial colposcopy. Assuming that they had not progressed during this time, they 
would be treated at 24 months, hence the increase seen (a small proportion of these 
patients would be expected to progress to CIN 2 and so would be treated prior to 24 
months). 
 
7.3.3 Total workload change and detection of high-grade disease 
Detection of high-grade disease is presented in Figure (10) and Table (48) to represent 
the outcome of cervical screening and colposocpy along with total workload increases.  
 
Figure (10): "least efficient" service- total workload increase vs detection of high-grade 
disease 
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Table (48):Percentage increase in detection of high-grade disease for the “inefficient” 
service under the one mild policy 
Time since new policy implementation  
6 months 12 months 18 months 24 months 30 months 36 months 
Change in detection of 
high-grade disease 43.5 23.7 22.4 22.9 23.6 24.0 
 
The improved detection of high-grade disease associated with the “inefficient” clinic type 
is in fact similar to that under the “efficient” clinic scenario, with an improvement of 24% 
expected when compared to the previous mild dyskaryosis referrals policy. However, the 
detection rate is highest after a longer period of time, since the follow-up policies adopted 
are likely to mean that disease will be detected at a later appointment (for example, the 
“inefficient” clinic type follows women for up to 24 months after a CIN 1 result at the 
initial colposcopy, and so high-grade disease would be detected in those women whose 
disease progressed during that time period). 
 
7.3.4 Waiting times 
The inefficiency of this third type of clinic is likely to have the greatest impact upon 
patient waiting times. Although the additional number of referrals is similar to that of the  
other two clinic types, the intensity of the follow-up and surveillance policies for this 
clinic type means that patients stay on the clinic register for longer, leaving less clinic 
time for new referrals. 
 
Patients attending units which run six or more clinics of this type per week are not 
expected to encounter delays in being offered an appointment beyond the recommended 
waiting time. However, if such a unit were to run five clinics per week, this would have a 
detrminetal effect upon the waiting time of new referrals with low-grade abnormalities. 
Within 6 months of the policy change, the waiting time model predicts that new low-
grade referrals will have to wait more than 4 weeks for their initial appointment, rising to 
20 weeks at the end of the first year. The situation is expected to continue to deteriorate  
thereafter, in the absence of additional clinics or improve clinic efficiency thereafter, as 
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the waiting list builds up. As before, new patients being referred with high-grade disease 
would be unaffected by these delays given their priority over patients with low-grade 
disease. 
 
 
7.4 Health Economics 
The ScHARR LBC model was adapted as described in Section 6.7 to give estimates of 
the cost-effectiveness of the new policy by relating the expected health gains to the 
increased cost of referring a significant number of additional women. Two separate 
scenarios were modelled, using both 3- and 5-year screening intervals.  
 
Table 49 summarises the results of the incremental cost-effectiveness analyses 
(comparing the new mild dyskaryosis policy against the previous policy): - 
 
Table (49): Incremental cost-effectiveness results 
Screening 
interval 
Cost per QALY 
gained 
3 years £5,521.07 
5 years £1,405.22 
Mixed-interval £3,258.30 
 
As mentioned earlier, these figures should not be assumed to be exact estimates of cost-
effectiveness, for the reasons described in Section 5.3. The costs are likely to be 
underestimates, since the LBC model takes no account of post-treatment follow-up, nor 
of follow-up for patients under surveillance for CIN 1 or HPV. Despite this, the change in 
policy would seem, based upon these figures, to be considered cost-effective to 
organisations such as NICE. 
 
Since the costs are likely to have been underestimated, sensitivity analyses have been 
performed to assess the impact of increasing the number of appointments per patient, and 
therefore the costs associated with diagnosing and treating women in the clinics. The base 
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case analysis assumes that each woman has one clinic appointment, which constitutes a 
colposcopy and any necessary treatment (with the exception of those diagnosed with 
invasive cancer). It would seem more realistic to assume two appointments per patient, as 
this would take into account the fact that treatment often takes place at a separate 
appointment, that women who are treated would often have a follow-up apointment to 
check for residual disease, and because many clinics employ surveillance strategies for 
women with low-grade disease, generating further appointments. Making this assumption 
the incremental cost per QALY associated with the new policy is estimated to be £2,897 
for a 5-year screening interval, £11,197 for a 3-year screening interval, or £6,753 for a 
mixed-interval strategy. Further sensitivity analyses have not been performed on the 
utility estimates due to a lack of suitable evidence concerning utility loss associated with 
colposcopy and treatment. 
 
It is anticipated that the true cost-effectiveness of the new policy would not be seen in the 
first few years following the policy change, because the improvement in detection of 
high-grade disease within the first year would only become apparent at subsequent 
screens for this group of patients. Given the more rigourous approach to detecting 
cervical disease which the new policy incorporates, the long-term benefits in terms of 
both costs and health benefits are expected to be greater than in the short-term. 
 
 
7.5 Sensitivity Analyses 
 
Given the expected impact of the new policy, particularly on clinic capacity, a series of 
sensitivity analyses were carried out through modifying other clinic protocols to 
ameliorate the implications of the new referral strategies. The impact of the following 6 
such additional policy changes was modelled: - 
  
§ Refer women to colposcopy only after 3 borderline smears; 
§ Adopt an age-related screening interval, such that women aged 25-49 are 
screened every 3 years, and those aged 50-64 are screened every 5 years; 
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§ Discharge women from the clinic after their treatment visit (i.e. offer no folow-
up appointments); 
§ Treat CIN 1 immediately; 
§ See and treat all patients with high-grade disease; 
§ Discharge women with negative colposcopy to cytological surveillance. 
 
As discussed in section 2.4, recommendations for strategies regarding the referral of 
patients to colposcopy services are produced by the NHSCSP directorate. A significant 
proportion of services were recognised to not follow national directives. The first change 
in clinical protocol examined were the adoption of the policy of patients requiring three 
borderline smears prior to referral. The model was constructed to assume current national 
policies regarding inadequate referral smear policies are followed to avoid complicating 
the process further. However, significant workload savings may also be achieved where 
this policy is not followed. 
 
The new national guidelines also include other changes in recommnended practice. As 
discussed in section 2.4, previously patients were invited for their first smear at 20 to 24 
years old, and patient recall patterns are organised locally, generally either 3 or 5 year 
periods. The new recommendation is for the first smear to be performed at the age of 25 
and the patient then has 3 yearly smear until 49, with patients from 50 to 64 have 5 yearly 
smears.(4)  This additional policy was modelled for both the “typical” and theoretically 
“least efficient” clinic. The “typical” service is modelled under current national practice 
data regarding “call-recall”, while the “least efficient” service was originally modelled as 
accepting patients referred from a three year recall strategy. 
 
As discussed previously, a significant number of services operate clinics with diagnosis 
and treatment at a single visit. This is known as “see and treat”, and is generally thought 
to be a more efficient method of managing patients. This analysis presents the impact of 
adopting a see and treat policy for all patients with high-grade disease, for the typical and 
“least efficient” clinic types, but not for the “most efficient” clinic, which already 
incorporates this policy.  
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The questionnaire returns indicated a range of policies regarding management of patients 
with CIN 1. Altering the national policy to recommend that all such women are treated 
immediately, rather than being followed up, would obviate the need for extensive follow-
up appointments, which is particularly relevant given the relatively slow progression rate 
between CIN 1 and CIN 2. 
 
The predicted impact on clinic workload and disease detection of discharging all women 
from the clinic after their treatment visit was modelled for the “typical” and “inefficient” 
clinics (the “efficient” clinic type already incorporated this policy). This was 
demonstrated to be the area with greatest variability in current clinical practice 
nationwide. 
 
New national policy recommendations include advice regarding the follow-up of patients 
if the referral smear is low-grade and the initial assessment is adequate and normal. In 
this circumstance the patient may be discharged to cytology surveillance. This approach 
is sometimes referred to as ‘fast in – fast out’, and its impact is explored further in these 
analyses. 
 
7.5.1 Impact of policy changes on “typical” clinic 
Figure (11) shows the predicted percentage increase in clinic workload for the “typical” 
clinic type, when compared to current practice, associated with the 5 additional policy 
changes mentioned above. 
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Figure (11): Impact of further policy changes on clinic workload (typical clinic) 
 
The results demonstrate the relative impact of each individual policy change on the 
expected workload for a typical clinic. The greatest reduction in workload is likely to be 
seen through discharging women following treatment, with no further follow-up in the 
clinic setting. This is primarily because residual disease which would have been picked 
up at follow-up visits now goes undetected until the next screening round, and so the 
longer-term impact of changing this policy may not be as great as the data for the first 3 
years suggest.  The second largest reduction in workload is seen through referring women 
to the clinic only after three borderline smears; although this is already national policy, 
the questionnaire results suggest that many health authorities prefer to refer women after 
2 borderline smears. If all women with CIN 1 were treated immediately rather than being 
entered into a surveillance programme, this would reduce the impact of the new mild 
dyskaryosis policy in terms of additional workload from 21% to around 15% after 3 
years. 
 
The impact of employing an age-related screening interval is seen to be minimal, as does 
that of treating all women with high-grade disease on a see and treat basis, since the 
majority of clinics already do this. Discharging patients with a negative colposcopy has 
0%
5%
10%
15%
20%
25%
30%
0 6 12 18 24 30 36
Months since policy change
%
 in
cr
ea
se
 in
 c
lin
ic
 w
or
kl
oa
d
1 mild
Age-related
screening
Discharge post-
treatment
Treat CIN 1
3 BNA
See & treat
high-grade
Fast in fast out
 87 
little effect for the same reason, plus the fact that only a small number of these women 
will have disease progression over a 6-month period. 
 
 
7.5.2 Impact of policy changes on “efficient” clinic 
Given the nature of the policies incorporated within the theoreticaly “most efficient” 
clinic, it would be impossible to reduce clinic workload any further, and therefore no 
sensitivity analyses have been conducted within this scneario. 
 
 
7.5.3 Impact of policy changes on “inefficient” clinic 
Equivalent analyses were performed on the theoretically most inefficient clinic, to 
identify potential areas for improvement in terms of clinic efficiency. Figure (12) shows 
the predicted impact of such policy changes: - 
 
Figure (12): Impact of further policy changes on clinic workload (inefficient clinic) 
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this scenario, the workload of such a clinic would be expected to be lower than before the 
new mild dyskaryosis policy was introduced. Again, this would not be the case in the 
longer term, as women with residual disease would be picked up at future screening 
rounds. Immediately treating all women with CIN 1 would also offset the impact of the 
mild policy considerably, with the percentage increase in workload being reduced from 
27% at 3 years to around 6%. Referring women after 3 borderline smears would have a 
similar effect on overall workload, and would represent considerable savings in terms of 
the number of clinic sessions required and would also mitigate the impact on patient 
waiting times. The introduction of either an age-related nationwide screening programme, 
a policy of treating women with high-grade disease at the initial visit, or of discharging 
women with a negative colposcopy would have less of an effect. 
 
 
7.5.4  National policy modelling 
The final modelling for policy changes performed is the combined effects of changing  
clinical protocols. The results on workload and detection of high-grade disease of three 
changes in clinic policies implemented sequentially in the “typical” service are given as 
an example of the effects on services if these NHSCSP recommendations were 
introduced into clinical practice. These changes are shown incrementally for the typical 
clinic in Figure 13: - 
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Figure (13): Impact of NHSCSP recommendations on clinic workload (“typical” clinic) 
 
These results emphasise the impact of adherence to national guidelines, particularly those relating 
to referral of women with borderline smears and of post-treatment follow-up. Adherence to all 
three policies in the future would reduce the level of clinic workload to a level below the 
corresponding figure prior to the mild dyskaryosis policy change. 
 
 
7.6 Model validation 
The first model validation performed is to compare the modelled services with the 
available national data. The total number of patients referred for colposcopy in the model 
was similar to those nationally (approx. 100,000 for abnormal cytology). The distribution 
of referred patients by smear category was also similar in the modelled services 
compared to national data returns. The estimates of the number of cancers detected in 
each period under the different policies was matched against incidence data from the 
latest Statistical Bulletin, which reported the number of cancers detected by screening in 
the 20-64 age group as 1,746. The pathway model predicted an incidence of 1,488 
cancers per year, which when coupled with cancers detected via appointments for clinical 
indications (estimated to be 18% of all colposcopy clinic workload) gives a figure of 
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1,755. The model was validated further through analysis of the breakdown of referrals to 
colposcopy by smear result. These figures were compared with data from the 2001-02 
KC65 returns, and found to be extremely similar.  
 
 
 
8.0 Conclusions and discussion 
 
Cervical screening directed towards the identification and treatment of ‘pre-invasive’ 
high-grade CIN has significantly reduced the incidence of, and mortality from, squamous 
carcinoma of the cervix in the UK. Appropriate selection of patients for referral to 
colposcopy services is fundamental to screening practice. Available evidence suggests 
that detection of high-grade disease is imporoved by changing current practice from two 
mild dyskaryosis smears being required prior to referral, to a single smear triggering 
colposcopy attendance. This is appreciated to increase number of patients referred to each 
service, but the full implications of a shift in policy are presented for here for the first 
time. The discussion of the implications of changing policies is divided into the sub-
sections presented in the results above.  
 
8.1 Clinical workload and detection of high-grade disease 
 
8.1.1 Total clinic workload.  
All services not currently seeing patients after a single mild dyskaryosis will experience 
significant increases in clinical workload if policy is changed. The numbers of extra 
clinics to cover demand associated with such a shift is related to current operational 
strategies. If the service is currently offering colposcopy appointments to patients in a 
wide variety of clinical situations (in this study “least efficient” service) then the total 
increase in number of clinics will be significant, with a 27% increase in workload over 
the first three years. The percentage change in workload over the same time period, is 
magnified (34.9%) for the “most efficient” service due to the limited number of clinic 
appointments currently generated per patient referred.   
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The “typical” service gives an indication of the national effect of implementing new 
guidelines. Although this “service” incorporates the 20% of services currently seeing 
patients after a single mild dyskaryosis, the average workload increase experienced in 
services nationwide would be 20.6% over three years. 
 
 
 
8.1.2 Workload by clinical activity 
The distribution of workload increases caused by new mild dyskaryosis referral is divided 
fairly evenly across areas of clinical activity: new referrals, surveillance colposopies and 
treatments. Increases in new referrals are characterised in the model by a large initial 
wave of workload. This is caused by the combined effect of those who are referred from 
the previous time period and who under the original strategy would have waited for 
repeat cytology, added to the patients within the time period following strategy change, 
who are referred with a single dyskaryosis. Once this period has passesd, the new referral 
group remains significantly elevated in all service types. Similar increases are seen in the 
surveillance groups for all service types, although very little surveillance is performed in 
the “most efficient” service under either referral strategy. As discussed in the results 
section, in this instance treatment is defined as any appointment intended to achieve 
treatment of CIN of any grade. Increases are also significant in all service types in this 
activity. 
 
8.1.3 Detection of high-grade disease 
To prevent cervical carcinoma by cervical screening, detection and treatment of high-
grade disease is of paramount importance. In the results detection of high-grade disease, 
and by implication its treatment, is used as a surrogate for coloscopy success. The 
increase in detection of CIN 2/3 is significant in all service types, 16.5% for the “typical” 
service, 25.0% and 24.0% for “most” and “least” efficient, respectively. Detection is 
again characterised by an initial “peak” in detection, with the large volume of new patient 
referrals in the first six month period. However, increased detection of high-grade disease 
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is sustained in the model data at three years from change in referral policies, and is likely 
to persist at these levels until disease prevalence is reduced in the community by ongoing 
screening practice.. 
 
   
 
8.2 Waiting times 
 
From a clinical perspective, the  waiting time analyses are the hardest to interpret in 
terms of implications on service activity. The construction of the model required the 
services to be populated from “no patients” in the service. This is performed by 
recruiting patients to the theoretical services on the basis of current cytology result 
reporting and predicting disease transition from published research. In terms of clinic 
activity this includes CIN only and patient care resulting from this. True clinic activity 
is of course more complex. Some services are involved in the long term care of women 
previously treated for micro- and macro-invasive disease and in the care of women with 
vaginal, vulval or peri-/anal intraepithelial neoplasia.  
 
As discussed below, the assessment of women with cervical abnormalities or 
gynaecologic symptoms is often performed in colposcopy clinics. Some patients may 
also require increased colposcopy surveillance as a result of being 
immunocompromised or as a consequence of  HIV disease. This results in true clinic 
activity being far greater than the management of patients with pre-invasive cervical 
disease, and the ability of services to accommodate with a significant increase in 
workload without effects on target and recommended waiting times presented is 
inaccurate. What the results do demonstrate is the significant effect that new referral 
strategies will have on services, particularly those currently running few clinics per 
week and operating in an “inefficient” service manner.  
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8.3 Health Economics 
Although a comprehensive economic analysis has not been performed due to 
inconsistencies between the clinic pathway model and the ScHARR model for assessing 
the cost-effectiveness of screening with LBC, the preliminary analysis suggests that the 
change in the mild dyskaryosis referral policy is cost-effective, with the benefits achieved 
through the improved detection of high-grade disease outweighing the additional costs of 
referring more women to the colposcopy clinics. Some of the costs of follow-up and 
surveillance were not included in the cost-effectiveness analysis, but these are not 
expected to increase the costs to a level at which the new policy would be deemed 
unacceptably expensive. The estimates derived suggest that the policy change is more 
cost-effectiven than many recent treatment interventions which have been recommended 
for use by NICE. 
 
 
8.4 Modification of workload increases 
 
It is expected that the increased detection of high-grade disease and QALY assessment is 
likely to be viewed as desirable to commissioning authorities for cervical screening. 
However, it is expected that some colposcopy services are likely to experience difficulty 
in implementing new referral guidelines without significant increases in the number of 
clinical sessions being operated. For some services increased activity will be inevitable, 
but others may find changes to clinical protocols advantageous to allow increased referral 
rates to be accommodated. It should be emphasised that every change in protocol may not 
be appropriate for each service, but they may provide a guide to where workload savings 
could be made.   
 
8.4.1 Access policies 
National referral policy recommendations have existed for 12 years. Referral strategies 
for borderline and inadequate smear categories have been the subject of extensive 
research and debate, and reflect the prevalence of true pre-invasive disease in these 
groups. However, there are psychological implications for patients following any non-
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negative smear result, and reassurance may well be a driving force behind early referral 
of patients with these smear states.(57) In the questionnaire phase of this exercise, we 
identified that over 60% of NHS services currently accept access to colposcopy services 
after two smears demonstrating borderline nuclear change, contrary to national guidance.  
 
In these services, considerable workload and waiting time savings are available by the 
adoption of the national recommendations; in the ‘high intensity’ service presented 
projected workload increases are reduced by over half (12.8% vs 27.0%), by the 
implementation of national criteria for borderline smear abnormalities alone; and just 
under half (10.9% vs 20.6%) for the “typical” service over three years. Detection of high-
grade disease over three years is however predicted to be significantly affected by 
changing referral patterns as a consequence of the reduced number of patients undergoing 
colposopy. These reductions are  12.9% with single mild referral plus 3 borderline 
referral compared to  24.0% for the “least efficient” service over the first three years. 
This change is 9.8% vs 16.5% for the “typical” service. This significantly blunts the 
advantages of policy changes now these referral policies are in place, and will become an 
issue for debate where these two borderline referral policies are in place.   
 
To avoid over complicating this model, services were assumed to see patients after three 
inadequate smears. In services seeing patients after a smaller numbers of consecutive 
inadequate smears, workload savings may be in the region of those for borderline smears, 
with less compromise in detection of high-grade disease, as these patients have much 
lower disease rates. This is discussed further in section 9.0.  
 
Changing age-related call-recall policy is a fundamental change in practice recommended 
by the new national guidelines for practice.(4) This will have a fairly marginal effect on 
the “typical” service in terms of colposcopy workload (18.6% for new call-recall vs 
20.6% for current practice), as a variety of policies exist nationally which are averaged to 
produce these results. More dramatic effects are seen when the individual modelled 
services are examined. The “least efficient” service currently operates a 3 yearly recall 
policy, and workload increases over three years reduce from 27.0% to 18.6% with the 
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change in policy. The “most efficient” service currently operates a 5 yearly recall policy 
at all ages. This service sees workload increases from 34.9% under current strategy to a 
dramatic 76.0%. Detection of high-grade disease is affected by any policy to increase 
screening intervals in any patient groups. However, in this model a single transition exists 
for CIN in patients of all ages. With increasing age, time of progression from one disease 
state to another may be reduced, thus detection of high-grade disease may be affected less 
than suggested above, as the model does not account for this.  
 
Included in the national colposcopy guidelines for practice management was advice 
regarding patients with symptoms or signs suggestive of cervical disease. Previous advice 
recommended patients presenting with post-coital bleeding or an abnormal looking cervix 
with normal cytology were seen in colposcopy. It is recognised that few of these patients 
benefit from colposcopy services, the prevalence of pre-invasive disease is low in this 
group, and they often require gynaecology services in a wider setting. The new guidelines 
recommend these patients are seen in general gynaecology, seeing colposocpy as a 
tertiary service only if cytological abnormalities are detected. KC 65 returns indicate that 
17% of colposcopy referrals are made for these “clinical indications”. In the national 
colposcopy questionnaire it was determined that 53% of colposcopy services are seeing 
patients if presenting with symptoms such as post-coital bleeding, and 70% of 
colposocpy services are seeing patients if the cervix is described as abnormal. These 
patients lie without the remit of this model which determines colposocpy practice based 
on cervical cytology referral only. It is not currently known how many patients will 
ultimately access colposocpy services after triage in general gynaecology. The possibility 
of incorporating this in future work is discussed further in section 9.0 
  
8.4.2 Follow up after normal colposcopy 
The new national colposcopy guidelines included new recommendations for the care of 
women referred with low-grade cytology found to have no evidence of CIN at 
colposcopy. 37.1% of colposcopy services currently perform colposcopy on a futher 
occasion for these patients, presumably to check for the presence of disese. Indeed, it has 
been demonstrated that women referred with abnormal cytology and normal colposcopy 
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assessment remain at higher risk of significant cervical disease than the background 
population. In addition, whilst the Receiver Operating Curves for colposcopy based on 
cytology approach an ideal ‘fit’, (58) false negative colposocopy remains inherent to the 
screening programme. However, repeat colposcopy may well have no basis in the 
immediate care of this patient group, and patients with a normal colposcopy are 
recommended to be ‘discharged’ to cytology follow-up.  
 
This so-called ‘fast in – fast out’ approach puts added emphasis on making a reliable 
diagnosis for the patient at the first visit, but for services not currently operating this 
policy, significant workload savings are available. In the presented “least efficient” 
service, the total workload increase is reduced from 27.0% to 22.6% without significant 
effect on detection of high-grade disease. Due to the number of services currently 
operating this policy, the effect is reduced in the “typical” service (20.6% vs 18.9%), but 
again there is no effect on the detection of high-grade disease.  
 
8.4.3 Management of low-grade disease 
Currently there is no consensus on the best management of women with biopsy proven 
low-grade disease, with approximately 30% of the services in the UK offering treatment, 
whilst others recommend conservative expectant management. This is a marked 
reduction in the use of treatment for low-grade disease from previous questionnaires. 
Longitudinal studies demonstrate regression of CIN 1 in a significant number of patients. 
This evidence is used to support management strategies involving surveillance of low-
grade cervical findings, particularly in patients of reproductive age, where multiple 
treatments may compromise the performance of the uterine cervix during pregnancy. 
However, services which employ a conservative approach will experience significant 
workload implications. Clinical workload implications may be ameliorated somewhat by 
shifting to more treatment orientated policies. For the “least efficient” service, even when 
CIN 1 treatment is performed at a deferred outpatient appointment, there are considerable 
workload savings available,  total workload is predicted to increase only 6.7% with 
treatment for CIN 1, versus 27.0% with six-monthly surveillance. Again, the effect on the 
“typical” service is reduced by the number of services offering treatment at some stage in 
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follow-up of CIN 1. Detection of high-grade disease is not presented as this is unaffected 
by change in policy.  
 
It will be noted that there are increases in workload with deferred treatment for CIN 1 in 
the “most efficient” service in treatment activity. This service is characterised by offering 
treatment on a “see & treat” basis to patients with CIN 1, and so increased appointments 
are generated by applying a policy of deferred treatment.  
 
The treatment of CIN 1 is a matter for discussion in individual services, dependent on the 
availability of colposcopists trained in treatment modalities, and the needs of the patient 
group. However, the national trends observed in clinical practice are away from treatment 
based management policies for low-grade disease, and increases in use of treatment for 
patients in this group may be agreed to be undesirable. 
 
8.4.4 Timing of treatment 
Policies incorporating diagnosis and treatment of CIN in a single visit (‘see & treat’), 
may be utilised to reduce workload implications of new referral strategies,and are widely 
used in the practice reported in the national questionnaire. Patients referred with 
moderate or severe dyskaryosis, in particular, are likely to have high-grade CIN requiring 
treatment, and in 61% of services this is offered. There are minimal workload savings to 
be made in all service types adopting this policy. While the number of clinic 
appointments for each patient referred reduces with the removal of a deferred treatment 
visit, the increased time required for a ‘see & treat’ visit, including the counselling 
involved, reduces any benefits which might instinctively be expected. Coupled with the 
need for training in what will constitute an extended role for many people practising 
colposcopists, it may be considered that any further increases in utilisation of ‘see & 
treat’ are undesirable and unattainable.  
 
8.4.5 Post treatment follow-up 
The most impressive workload savings are expected with the discharge of patients 
following treatment for CIN. The “typical” service, where workload is predicted to rise 
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by 27.0% under single mild referral, this is almost cancelled out by a change in policy to 
discharge post-treatment, with an increase of just 2.8% over three years. For the “least 
efficient” a predicted increase of 27.0% under single mild referral is reversed to a 
reduction of workload by 3.3% after three years by not offering follow up after treatment. 
In the national questionnaire the greatest range of clinical management policies was 
found in post treatment care. It is well documented that certain groups of patients are at 
risk of residual/recurrent disease, particularly patients over 50 years old, and those where 
disease is not fully removed at the internal (or endocervical) margin of treatment, and 
these “at risk” groups are often targeted for further colposcopy assessment. However, the 
role of colposcopy in this setting is debated, and the new national guidelines recommend 
that cytology is adequate assessment for the majority of patients, whereas it may be more 
appropriate to re-treat the small group of patients over 50 with evidence of disease at the 
internal resection margin. Services using colposopy extensively in patient follow-up after 
treatment may find significant savings made by reducing its use.  
 
8.4.6 Combined changes to National policy 
The final modelling results show the combined changes of the new national guidelines 
employed in the “typical” colposcopy service. Introducing the three guidelines: three 
borderline referral, “fast in – fast out” and discharge post-treatment, allows the referral of  
single mild referral with an overall reduction in workload of approximately 10%.  
However, this is associated with a reduction in the detection of high-grade disease from 
10.1% to 6.0%. 
  
 
8.5 Summary and validation 
Single mild dyskaryosis referral is expected to, and in this modelling exercise, delivers 
improved detection of high-grade cervical pre-invasive disease. This, naturally, implies 
significant increases in colposcopy clinic activity for all services. Some services, in this 
report known as “inefficient” services, could accommodate this increased workload with 
changes in clinical practice. However, some changes in practice are seen to compromise 
detection of high-grade disease at least in the short-term. Some services, in this report 
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noted to approach the practice of an “efficient” services,  cannot change  clinical 
protocols to improve patient throughput, and may require significant increases in 
resources. This will be further exacerbated if changes in age-related “call-recall” strategy 
are also implemented to a region currently seeing patients on a five year recall basis.  
 
In terms of model validation, due to the excellent response in colposcopy questionnaire 
return, the authors’ confidence in the model is high because it is based on data from a 
significant proportion of national services. The modelled increases are not unprecedented. 
Pilot studies introducing the reflex testing of low-grade of low-grade smears for Human 
Papilloma Virus (HPV) and referral of patients who test positive, found high rates of 
virus positivity (>85%) in the mild dyskaryosis groups. As a consequence the majority of 
patients were referred after a single mild smear, and colposcoy services were quickly 
overwhelmed. In subsequent discussion, this increased workload was thought to represent 
a ‘one-off’ wave of referrals; the model presented predicts the increased workload will be 
sustained. 
 
One service local to the authors’ unit has shifted from two mild to single mild referral 
strategies, and reports a significant increase in colposcopy workload.  
Conversely, another local unit has recently shifted from the 2 borderline to 3 borderline 
access policy, and is experiencing significant workload savings. It is hoped both these 
services will be amenable to examination of changes in workload for compare with the 
predicted modelled outcomes. 
 
 
9.0 Further Work 
 
The recommended “roll-out” of the use of Liquid-Based Cytology (LBC) as the primary 
screening method will have an impact upon the number of women being referred to 
colposcopy services, due to the reduction in inadequate smears from 9% to around 3%. 
This reduction would also reduce the number of women being referred to colposcopy 
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with persistently inadequate smears, many of whom test negative at colposcopy. It would 
be possible to re-model services with respect to LBC.  
 
For many years it has been known that cervical cancer and CIN are caused by certain 
strains of Human Papilloma Virus (HPV). It is now possible to test for HPV on cervical 
swab samples and LBC diluent, which has led to areas of recommended implementation, 
for example, triage of low-grade smears and triage of patients following treatment. There 
is also scope for expansion of the model to include the impact on colposcopy services of 
the introduction of HPV testing in the community and in colposocpy practice.  
 
The results presented here have attempted to give the nationwide impact of the new mild 
smear policy, in additional to the impact on two example services to demonstrate the 
likely range of the effect on colposcopy services. Of more practical use to clinicians, 
would be a version of the model into which each clinic’s population data and clinical 
policies could be input, to predict the impact of the policy, and indeed that of any 
subsequent changes to policy management variables such as follow-up and surveillance. 
This could be in the form of a version of the model downloadable from the ScHARR 
website, which would enable decision making at a local level in order to improve clinic 
efficiency and throughput of patients. 
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